Attached files
| file | filename |
|---|---|
| EX-32.2 - PetLife Pharmaceuticals, Inc. | ex32-2.htm |
| EX-32.1 - PetLife Pharmaceuticals, Inc. | ex32-1.htm |
| EX-31.2 - PetLife Pharmaceuticals, Inc. | ex31-2.htm |
| EX-31.1 - PetLife Pharmaceuticals, Inc. | ex31-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K
| [X] | ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the fiscal year ended August 31, 2016
| [ ] | TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
Commission file number: 000-52445
PETLIFE PHARMACEUTICALS, INC,
(Name of registrant as specified in its charter)
| Nevada | 33-1133537 | |
| (State or other jurisdiction of | (I.R.S. Employer | |
| incorporation or organization) | Identification No.) | |
38 West Main Street Hancock, MD |
21750 | |
| (Address of principal executive offices) | (Zip Code) |
(844) 473-8543
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act: None
Securities registered pursuant to Section 12(g) of the Act:
Common Stock, $0.001 par value
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes [ ] No [X]
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act. Yes [ ] No [X]
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [ ]
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [X] No [ ]
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. [ ]
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definition of “accelerated filer”, “large accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer [ ] | Accelerated filer [ ] | Non-accelerated filer [ ] | Smaller reporting company [X] |
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [ ] No [X]
The aggregate market value of the common stock of the registrant held by non-affiliates as of November 28, 2014 the last business day of the registrant’s most recently completed first fiscal quarter based on the closing sale prices of the registrant’s common stock on that date as reported on the OTCQB maintained by OTC Markets Group, Inc. was $15,338,480. For purposes of this computation, all officers, directors, and 5 percent beneficial owners of the registrant are deemed to be affiliates. Such determination should not be deemed an admission that such directors, officers, or 5 percent beneficial owners are, in fact, affiliates of the registrant.
The number of shares of the registrant’s common stock outstanding as of December 6, 2016 was 59,686,171 shares.
TABLE OF CONTENTS
2
The document (including information incorporated herein by reference) contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which involve a degree of risk and uncertainty due to various factors affecting PetLife Pharmaceuticals, Inc. (Formerly Clear TV Ventures, Inc. and formerly Eco Ventures Group, Inc.)
Forward-Looking Statements
This Annual Report on Form 10-K contains forward-looking statements, including, without limitation, in the sections captioned “Business,” “Risk Factors,” and “Management’s Discussion and Analysis of Financial Condition and Result of Operations,” and elsewhere. Any and all statements contained in this Current Report that are not statements of historical fact may be deemed forward-looking statements. Terms such as “may,” “might,” “would,” “should,” “could,” “project,” “estimate,” “pro-forma,” “predict,” “potential,” “strategy,” “anticipate,” “attempt,” “develop,” “plan,” “help,” “believe,” “continue,” “intend,” “expect,” “future,” and terms of similar import (including the negative of any of the foregoing) may be intended to identify forward-looking statements. However, not all forward-looking statements may contain one or more of these identifying terms. Forward-looking statements in this Annual Report may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) our future financial performance, including any such statement contained in a discussion and analysis of financial condition by management or in the results of operations included pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”), (iv) our beliefs regarding potential clinical and other health benefits of our PetLife products, and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above.
The forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon our current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which we have no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, our inability to obtain adequate financing, the significant length of time and resources associated with the development of our products and related insufficient cash flows and resulting illiquidity, our inability to expand our business, significant government regulation of our business and the healthcare industry, the results of clinical studies or trials, lack of product diversification, volatility in the price of our raw materials, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and our failure to implement our business plans or strategies. A description of some of the risks and uncertainties that could cause our actual results to differ materially from those described by the forward-looking statements in this Annual Report appears in the section captioned “Risk Factors” and elsewhere in this Annual Report.
Readers are cautioned not to place undue reliance on forward-looking statements because of the risks and uncertainties related to them and to the risk factors. We disclaim any obligation to update the forward-looking statements contained in this Annual Report to reflect any new information or future events or circumstances or otherwise.
Readers should read this Annual Report in conjunction with the discussion under the caption “Risk Factors,” our financial statements and the related notes thereto in this Annual Report, and other documents which we may file from time to time with the SEC.
All references in this Form 10-K that refer to the “Company,” “PetLife Pharmaceuticals, Inc..”, “Registrant,” “we,” “us” or “our” are to Petlife Pharmaceuticals, Inc., a Nevada formed corporation.
3
PetLife Pharmaceuticals, Inc. (PetLife) has developed and is launching a new generation of potentiated veterinary cancer medications and nutraceuticals, under its new tradename VitalzulTM, based on the same patented formula “Escozine” and production processes that have been scientifically proven as an effective treatment for cancer in humans for years. Escozine (for humans) is currently sold as either a nutraceutical or prescription drug in 40 countries including the US.
Historical Company Information
We were incorporated on April 5, 2002 under the laws of the State of Nevada as “Aztek Ventures Inc.” Effective November 13, 2007, we filed a Certificate of Amendment to our Articles of Incorporation to change our name from “Aztek Ventures Inc.” to “Genesis Uranium Corp.” Effective April 21, 2008, we amended our Articles of Incorporation to change our name from “Genesis Uranium Corp.” to “Vault Technology Inc.” to reflect the change in our business focus beyond solely that of uranium exploration. Effective July 10, 2009, we filed a Certificate of Amendment to our Articles of Incorporation to change our name from “Vault Technology, Inc.” to “Modern Renewable Technologies, Inc.” (“Modern”). On May 27, 2011, Modern, merged with Eco Ventures Group, Inc., and the name of the Company was changed to Eco Ventures Group, Inc. On July 18, 2013, the Company declared a 15-for-1 reverse stock split for all of its common and preferred stock. On June 26, 2014, Eco Ventures Group, Inc. entered into an Agreement and Plan of Merger with its subsidiary, PetLife Pharmaceuticals, Inc., a Nevada Corporation, with PetLife Pharmaceuticals, Inc. being the surviving entity. As part of that merger, the name of the Company was changed to PetLife Pharmaceuticals, Inc. and each 20 shares of our common stock were exchanged for one share in the surviving company. Effective August 12, 2014 we completed the closing of the Share Exchange Agreement and the acquisition of Petlife and changed our name to Petlife Pharmaceuticals, Inc. Effective July 19, 2016, we agreed to complete a subsidiary merger in which we effectively complete a 1 for 5 reduction in our outstanding shares. All references herein to the number of shares outstanding and per-share amounts have been retroactively restated to reflect both the reverse stock split on July 18, 2013, the exchange ratio in the merger with PetLife Pharmaceuticals, Inc., and the reduction in September 2016.
4
Business of PetLife Pharmaceuticals, Inc.
PetLife Pharmaceuticals, Inc. (PetLife) has developed and is launching a new generation of HP (high potency) veterinary cancer medications and nutraceuticals, under the new tradename VitalzulTM, based on the same patented formula “Escozine” and production processes that have been scientifically proven as an effective treatment for cancer in humans for years. Escozine (for humans) is currently sold as either a nutraceutical or prescription drug in 40 countries including the US.
Given the histology (the similarity of the cellular biology) between humans and dogs and cats and the growing body of new preclinical research (UCSD) establishing the effectiveness of Escozine for the treatment of animals, PetLife has licensed the worldwide rights to formulate, package and market a new product line, “VitalzulTM.”
The lead for our FDA approval of the pharmaceutical version of VitalzulTM will be Dr. Vivek Ramana, our Chief Medical Officer, who has greater than 20 years of experience in the pharmaceutical industry and has worked on more than 25 drugs that have been approved by the FDA. Dr. Ramana has more than four years’ experience working with Escozine and is in the final stages of having it approved as an Oncology drug for humans in India in partnership with Medolife. His combined professional experience and personal knowledge of Escozine and VitalzulTM gives Petlife great confidence in his ability to manage the process, adhere to the timelines and maintain the project budget.
The Company’s products have been demonstrated as a preventative and a treatment of cancer, and to dramatically improve the quality of life, and extend the longevity of pets with cancer — without the painful, debilitating side effects of toxic, conventional chemotherapy.
Summary
We have developed and are launching a new generation of high potency veterinary cancer medications and nutraceuticals, based on the patented “Escozine” formula. The Company’s production processes uses polarization technology to potentiate the main ingredient (scorpion venom), which dramatically increases its therapeutic effectiveness. Its use by medical professionals across the globe have shown scientific evidence as being effective for cancer in humans.
“Escozine” has been used for years to treat humans with cancer in many countries and its positive results are backed by numerous scientific research, pre-clinical and clinical observations that confirm its safety and efficacy. It is registered and certified for oncological treatment by the Minister of Health in the Dominican Republic, and is registered and distributed in six countries (Dominican Republic, Vietnam, Russia, Belarus, Nigeria and Kazakhstan).
VitalzulTM is an innovative polarized, potentiated bioactive peptide extracted from the Blue Caribbean Scorpion ( Rhopularus Princeps) which contains amino acids, proteins and minerals. Medolife filed a patent in 2012 for their scorpion based venom product and polarization technology (Patent # US 8,097,284 B2). The polarization technique acts as a delivery system and additionally, amplifies the highly positive charges in extracellular membrane in VitalzulTM. One of the main components of VitalzulTM , Chlorotoxin (CTX), a 36 amino acid peptide, has a high positive charge at pH 7, which blocks small conductance chloride channels. It binds preferentially to cancerous or any abnormal cells leaving the normal cells intact.
At the molecular level, the cancer cells of humans, cats and dogs are quite similar. With respected scientific research (UCSD and others) establishing Escozine as an effective potential solution for pets, we have licensed the rights to use Medolife’s patented formula and manufacturing process to launch “Vitalzul™” — a line of over-the-counter nutraceuticals, infused dog and cat ‘treats’ and prescription strength pharmaceuticals for pets.
5
PetLife’s main product, Vitalzul™ inhibits blood vessels formation in solid tumors. Chlorotoxin blocks trans-membrane fluxes of chlorine and regulates the adjusting of cell growth, cell division, metastasis and induces apoptosis (dose dependent) that leads to tumor cells death. The regulating of activity of the potassium (K+) 3-4 kDa, sodium (N+) 6-8 kDa and chloride (CL+) voltgate ionic channels of the tumor cells leads to growth arrest and causes cell death (apoptosis); additionally, calcium dependent potassium channels inhibit growth of other cancer cells.
PetLife’s products are produced to the highest industry standards in a US FDA-approved manufacturing facility, Sampson Pharmaceuticals, located in Commerce, California.
The National Cancer Institute reported that in the United States alone, nearly 6 million dogs and 6.5 million cats are diagnosed with cancer annually with dogs being 35 times and cats 40 times more likely to suffer from cancer than humans. Sixty percent of dogs and cats over six years of age will be diagnosed with cancer.
In the United States over 92 million households own a dog or cat, representing 83.3 million dogs and 95.6 million cats. Consumer spending on domestic companion animals in the United States alone is expected to reach over $60.28 billion in 2015, with over $13 billion being spent on over the counter medications. Demand for domestic pet health products is expected to grow approximately 4 - 6% annually through 2018
PetLife is launching its first product — a nutraceutical version of Vitalzul™ – in the fall of 2017. A line of Vitalzul for PetsTM dog and cat treats is scheduled for launch in the first quarter of 2018.
PetLife plans to apply to the FDA in the fourth quarter of 2016 to begin a New Animal Drug Application for prescription strength version of VitalzulTM. Although there can be no assurance the FDA will work this quickly, the Company anticipates FDA approval of its prescription strength products in the second half of 2018, and intends to roll out those products shortly thereafter.
The Company has a developed a sophisticated, multi-channel marketing strategy, to be implemented in the second half of 2017, that includes direct sales, retail, veterinarian vertical market, affiliate sales and infomercials for its nutraceutical formulation.
Corporate Overview
PetLife Pharmaceuticals, Inc. is a registered U.S. Veterinary Pharmaceutical company whose mission is to bring its scientifically proven, potentiated bioactive medication and nutraceuticals — “Vitalzul™” — to the world of veterinary oncology. The Company specializes in the research, development, sales and support of advanced drugs and nutraceuticals for pet cancer and autoimmune related diseases such as arthritis.
In humans, Medolife has been successfully marketing its Escozine products for cancer prevention and treatment for 7 years with distribution in 40 countries. Since the histology (cellular biology) of human, dogs and cats is quite similar at the molecular level, PetLife has licensed from Medolife the worldwide rights to formulate, package and market VitalzulTM.
6
Business Strategy
| ● | Initially, enter the market with an oral nutraceutical version of Vitalzul™ with a focus on the oncology needs of dogs and cats. | |
| ● | Raise capital through traditional means, including through this private placement of securities, additional private placements, public offerings and/or bank financings. | |
| ● | Apply for FDA approval of the Caribbean Blue Scorpion animal pharmaceutical drug, VitalzulTM for cancer treatment, a prescription strength oral pharmaceutical as well as a concentrated intravenous and injectable version for direct administration to a tumor. | |
| ● | Concurrently develop edible dog and cat treats that are infused with Vitalzul’s active ingredients that deliver preventative benefits for both dogs and cats. |
FDA Process, Cost and Time Line
The Company plan outlines the necessary studies and regulatory actions required to move VitalzulTM thought the Food and Drug Administration (“FDA”) and Center for Veterinary Medicine (“CVM”) approval process.
The lead for our FDA approval of the pharmaceutical version of VitalzulTM will be Dr. Vivek Ramana, our Chief Medical Officer, who has greater than 20 years of experience in the pharmaceutical industry and has worked on more than 25 drugs that have been approved by the FDA. Dr. Ramana has more than four years’ experience working with Escozine and is in the final stages of having it approved as an Oncology drug for humans in India in partnership with Medolife. His combined professional experience and personal knowledge of Escozine gives Petlife great confidence in his ability to manage the process, adhere to the timelines and maintain the project budget.
Dr. Ramana has provided Petlife with a time line of approximately 24 months to successfully complete the required clinical studies and register the pharmaceutical version of VitalzulTM with the FDA/CVM. We will also push to fast track the drug and can potentially have it approved as a compassionate use drug for pets in as little as nine months.
During the initial stage the drug will be analyzed to establish its structure, stability and toxicity. This stage will establish the ability to produce a stable, replicable drug product supply for the subsequent clinical studies in animals. This stage is estimated to take 3-9 months to complete at a cost of approximately $700,000.
The second stage is pre-clinical development. In this stage, Innovision Therapeutics will perform the studies necessary to establish the safety of the product. These studies include toxicology and dosing studies as well as establish the pharmokinetics and pharmodynamics of the drug. Essentially we want to learn what the drug does to the body and what the body does to the drug. This stage is estimated to take between 9 and 24 months. Many of these studies can be performed during the initial stage of the project if funding is available. The estimated cost of this stage is approximately $2,200,000.
In the third stage will include standard FDA phase I, II and III studies on dogs. These studies will establish safety and efficacy of the drug in a canine model and allow for the determination of appropriate dosing. Some of these studies can be run concurrently with earlier stages. The estimated to take between 12-24 months at accost of $3,600,000.
Based on the information provided in our Development Plan, assuming immediate full funding allowing concurrent studies, we expect to complete our FDA submission within 24 months.
The FDA/CVM registration is only necessary for the pharmaceutical version products Petlife wishes to sell globally. The nutraceutical version, pet food, treats and other products do require FDA/CVM approval under the Nutraceutical Division. Having this stamp of approval and completing these necessary tests will allow Petlife to make the necessary claims on the product label and in its advertising programs. This will move Petlife from a company with lots of anecdotal evidence and a few clinical trial to one with certified studies and evidence meeting all of the necessary requirements by the FDA/CVM.
7
The Company’s VitalzulTM Product
Escozine™ was originally developed and commercialized by Medolife Corp. in 2007. Until 2007, this natural medicine has only been available in Cuba, where it is known as Escozul, or its more diluted homeopathic version called Vidatox. Medolife currently holds the exclusive patent license, (United States patent # 8,097,284 B2) of the bioactive peptide and polarization technology used to make the Polarized Dilute Blue Scorpion Venom. Escozine™, is registered and certified for oncological treatment by the Minister of Health in the Dominican Republic. Escozine™ is currently registered and distributed in six countries (Dominican Republic, Vietnam, Russia, Belarus, Nigeria and Kazakhstan).
Studies show that Medolife’s US Pharmaceutical Corporations’ patented polarization technique (US Patent # 8097284 B2) increases the delivery of the scorpion venom into cancer cells which amplifies the effectiveness of Escozine™ dramatically compared to Cuban products Escozul or Vidatox. The product, VitalzulTM, is not produced or sold by Medolife or PetLife and neither Medolife nor PetLife rely on this product in any way. Medolife has its own independent source of Blue Scorpion venom in the Dominican Republic and has established the world’s first Scorpion reservation which is 50,000 square meters and can produce sufficient doses to meet global demand. Products are currently sold direct, through online marketing to over 40 countries, as well as to six countries where the product has been registered (Dominican Republic, Vietnam, Russia, Belarus, Nigeria and Kazakhstan). In 2014, Medolife granted an exclusive global license for production, marketing and sales of all veterinary applications of the patent to PetLife, for all applications of VitalzulTM, including the nutraceutical and FDA approved versions.
Escozine™ serum has demonstrated promising results in human preclinical studies as reported by Innovation Therapeutics, Inc. In a case study presented by health care provider, Dr. Alisher Kasimov. a 19-year-old male patient from Uzbekistan was diagnosed with medulloblastoma (brain tumor) in 2008. His medical history included radiation therapy for lumbar spine metastasis (from April 2011 to December 2012), including reported evidence of lumbar metastasis in February 2013, which was confirmed by MRI scan. On June 24, 2011, due to recurrence of the medulloblastoma cancer, the patient underwent surgery at the neurological clinic in Yekaterinburg (Russia). The patient completed other more traditional procedures. The biopsy result was that the medulloblastoma remained. On September 10, 2010 the tumor size was 33-20-18mm, then on September 5, 2011 the tumor was 34-18-22mm. The traditional therapy during 2011 through 2012 showed no material effect on the tumor. On March 5, 2013 the patient was started on Escozine orally and through nasal. After three months of taking Escozine, the tumor size was slightly decreased. After four months of Escozine therapy, tests showed no recurrence of the tumor.
Escozine has been used in combination with chemotherapy, radiation, hormone therapy and other conventional treatments. In 2007, Medolife collaborated with Atheris Laboratory in Switzerland, one of the world leaders in the study and analysis of crude venoms, to confirm that the venom of Rhopalurus Junceus from Cuba and Rhopalurus Princeps from Dominican Republic both share similar properties and have similar mechanisms of action in cancer cells.
8
Polarized Dilute Blue Scorpion Venom solution has proven to lead to more apoptosis (cancer cell death) in humans and animals, in comparison to non-polarized Dilute Blue Scorpion Venom solution. Additionally, polarized Dilute Blue Scorpion Venom solution can be used with gold nanoparticles as an intermediary agent to increase the targeting and binding preferences of Polarized Dilute Blue Scorpion Venom solution with abnormal or malignant cells in humans as well as in animals. The inclusion of gold nanoparticles, as the intermediary agent for the drug version further enhances the targeting and binding preferences of the Polarized Dilute Blue Scorpion Venom solution with abnormal or malignant cells in humans as well as animals.
One component of PetLife’s licensed patent is for the process of polarizing the dilute Blue Scorpion venom; the patented technology involves the circulation of the dilute solution past a series of electromagnets, which are generating resonating field with the Scorpion Venom therapeutic components, such as small molecular peptide, chlorotoxin (CLTX). The benefits of ingesting polarized Escozine dilute scorpion venom solution and its main ingredient are well documented through the clinical observations of well-known scientists in this field like, Dr. Omran, Dr. Stöcklin, Dr. Philippe Favrea and Dr. Ramon Feliz and include:
| ● | Reduces pain. | |
| ● | Enhances the recipient’s immune-system. | |
| ● | Reduces cancerous cell multiplication. | |
| ● | Inhibits new blood vessel formation in tumor | |
| ● | Improves quality of sleep. | |
| ● | Reduces inflammation. | |
| ● | Dramatically reduces the painful side-effects of chemotherapy and radiation treatment. | |
| ● | Improves appetite |
From statements in the patent document, polarized blue scorpion venom delivers an array of health benefits. According to extensive research contained in the 2012 UCSD Moore’s Cancer Center report, and other studies, patients administered with polarized blue scorpion serum solution frequently experienced the following health benefits: improved quality of life, increased survival rate, and tumor remission. Many patients who have used polarized blue scorpion venom in their treatment have experienced different degrees of these stated benefits. The degree of benefits of any particular patient is impacted by the patient’s stage of cancer, genetic issues, condition of vital organs, continued exposure to environmental toxicity, lifestyle choices and other factors.
PetLife will initially develop dedicated cancer preventative products, such as animal treats. These products are designed to prolong pets’ lives when taken consistently. The Company anticipates this will drive sales for PetLife as clients adopt these types of products as part of their pet’s normal daily diets. Part of PetLife’s sales and marketing framework is to not only sell the products to animals post cancer diagnosis, but to educate owners on cancer and autoimmune prevention. PetLife’s preventative animal treats, for example, are an excellent way for pet owners to promote lasting health and viability for their companions.
PetLife anticipates developing the following products for the cancer preventative products:
| ● | Vitalzul Preventative – a natural pet treat preventative |  | |
| ● | Vitalzul Tabs – a natural daily pet preventative tablet | ||
| ● | Vitalzul Pet Foods –natural preventative foods |
9
VitalzulTM has demonstrated an effect on several different cancer types. With inexpensive modifications, PetLife may be able to create cancer specific products that may increase sales. The following are the top veterinary cancer types that PetLife intends to target:
| ● | Lymphoma or Lymph sarcoma | |
| ● | Hemangiosarcoma | |
| ● | Osteosarcoma | |
| ● | Mast Cell Tumor | |
| ● | Melanoma | |
| ● | Squamous Cell Carcinoma | |
| ● | Mammary Carcinoma | |
| ● | Apocrine Gland Carcinoma (Anal Sac) | |
| ● | Transitional Cell Carcinoma | |
| ● | Soft Tissue Sarcoma | |
| ● | Lymphoma | |
| ● | Squamous carcinoma | |
| ● | Fibrosarcoma | |
| ● | Lung tumors | |
| ● | Brain tumors | |
| ● | Nasal tumors | |
| ● | Liver tumors |
When surgery is difficult to perform, PetLife has designed three products for differentiated intake protocols for home and veterinary usage.
| ● | Oral / Rectal - Home oral and rectal administration of the VitalzulTM liquid makes the animal easy to treat. The solution is colorless and odorless and can be administered through a droplet or enema. This is an effective tool which clients can use in the convenience of their home. | |
| ● | Injectable/Intraveneous - The injectable/intraveneous version can be used by veterinarians to directly inject the product into the tumor for effective, targeted high dose treatments. This will increase sales with vets who will have an effective in clinic, targeted product will require clients to bring their pets into the vet clinic for treatment. |
PetLife, through the work of its analytical scientists, has identified a diversity of diseases that it believes will respond positively from treatments with the Vitalzul™ nutraceuticals and drugs. The diseases below illustrate those areas of potential expansion beyond the current focus on veterinary oncology related illnesses. The expansion of the application of PetLife’s products and technical knowledge into other health related areas will require the addition of skilled research scientists and pharmacological experts. PetLife will expand its market reach and increase its revenue by treating other diseases.
PetLife intends to also develop products for pets in the following areas:
| ● | Arthritis: Arthritis (or osteoarthritis) is a slowly progressive, degenerative disease of the joints for which there is no cure. However, VitalzulTM may be able to help to prevent, delay, and manage arthritis in dogs or cats. Arthritis affects 1 in 5 dogs over the age of 7 and over 90% of geriatric cats have arthritis; currently 12 million cats have arthritis. | |
| ● | Hepatitis: As with humans, Hepatitis in dogs and cats affects the liver. This contagious disease includes symptoms such as fever, vomiting and diarrhea accompanied by abdominal pain. Furthermore, Hepatitis may lead to kidney damage. Approximately, 12% of dogs and 40% of cats get Hepatitis. |
10
| ● | Lyme disease: Lyme disease is a dangerous bacterial disease that can cause irreversible damage to a companion animal’s health. About 5% of dogs contract Lyme disease while the statistics for cats is nominal. |
Global Market for VitalzulTM and the Company’s Products
The global veterinary pharmaceutical industry is composed of various veterinary health products including biological, veterinary pharmaceuticals and medicated food additives. Over the past few years, the range of animal health products has diversified, currently encompassing metabolic drugs, reproductive aids, anti-ineffectives, feed additives, imaging diagnostics, vaccines, parasite control, and topical solutions. Veterinary products have emerged for treating chronic diseases such as cancer, osteoarthritis and cardiovascular disease. Pet owners, more than ever before, are spending a larger proportion of their income to take care of their pets’ health.
In the future, the global market for pet health products is expected to grow by an average of 4 - 6% annually and become more specialized. The major drivers will be: (1) the continued strengthening of the bond between owners and their animal companions, (2) increasing companion animal owner awareness and willingness to pay for care, (3) increasing occurrence of cancer in dogs and cats than people while only a fraction are treated because of prohibitive costs, (4) offering an FDA drug at competitive prices, and potentially more effective, as an incentive for more pet owners to treat their pets and extend their duration and quality of life. Companion animals have come to play an important part in the lives of many people. Unsurprisingly the bond between companion animals and people continues to strengthen in parallel to the market for products that contribute significantly to the health and well-being of these animals, such as the products offered by PetLife.
The current focus of the Company’s market is veterinary oncology, a branch of veterinary medicine whose emphasis is dealing with cancer diagnosis and treatment in animals, especially companion animals. Over the years, the number of animals dying of cancer has increased. For example, approximately 45% of dogs aged ten years and above die of cancer. Part of PetLife’s product expansion will include an injectable version that will focus on decreasing and eliminating tumors that are accessible to direct injection
PetLife realizes the parallels between animals and their owners regarding certain conditions, such as poor diet, and its consequences. Overall, the companion animal segment is considered to be the health segment that parallels the human pharmaceutical sector. Many of the innovations in human medicine, at least in terms of new medications, are subsequently adapted and tailored to suit companion animals, like Vitalzul™. It is therefore no surprise that Vitalzul’s studies have paralleled the Escozine™ for humans’ studies.
The global animal health market is consolidated with the top ten players controlling the majority share of the market. For many years the largest players in the companion animal market have been Merial and Zoetis. However, the market has seen considerable consolidation mainly through acquisitions and mergers. Proposed mergers and acquisitions are monitored very carefully by governments around the world (such as the Directorate General for Economic and Financial Affairs in the European Union and the United States Federal Trade Commission) to protect the consumer from reduced competition, price increases, and reduced innovation.
Medication and treatments for veterinary cancer are limited and largely ineffective - mainly aimed at temporarily delaying disease progression rather than effective treatments. The veterinary health market for companion animals has grown slowly but steadily by 4% - 6% annually while companion animal expenditures has grown to more than 6.9% compound annual growth rate.
11
While the U.S. represents the biggest regional market for animal medication, Asia-Pacific region represents the fastest growing market for pet medication with annual dollar sales in the region growing at an annual average of 10.5%. This can be attributed to factors such as increasing income, improvement in per capita consumption per animal, improved living standards, as well as increased pet populations in various regions all over the world. About half of Brazilian households have a dog, more than any other country, according to data tracker Euromonitor, and pet food sales there rose 10 percent to $5.6 billion last year, trailing only the U.S. and U.K. in the $71 billion worldwide market.
Despite remaining challenges in the overall economy, the pet industry has remained unshaken and has been less affected by the recent global recession than other retail sectors. Over the past years, the United States and the United Kingdom have been the leaders in the pet industry. However, today there are a number of other countries that are coming out as players in the global pet industry. The trend in world pet industry has increased tremendously, which is a clear indication of the growing market for veterinary oncology services.
Market in the United States
The veterinary oncology market in the United States is expected to grow mainly due to an increase in the pet population in the United States. People’s attitude towards companion animals has changed, as most pet owners now treat their pets as family members. In a report by Global Industry Analysts, Animal Medication: A Global Strategic Business Report, the authors indicate that animal care often mirrors the trends in human health care. Diagnosis and disease monitoring in veterinary medicine, particularly for companion animals, has also followed trends in human medicine. Diagnostic imaging techniques, such as ultrasonography, computed tomography (CT), and magnetic resonance imaging (MRI), have become commonplace and many veterinary practices have in-house analyzers for clinical chemistry and hematology, as well as rapid patient-side tests, e.g., for infectious agents.
The National Cancer Institute reported that nearly six million dogs in the United States alone are diagnosed with cancer annually, with dogs being 35 times more likely to suffer from cancer than humans. Over six years of age, sixty percent of America’s 83.3 million dogs and 95.6 million cats will be diagnosed with cancer. Unfortunately, only an estimated 10% of those diagnosed receive treatment. PetLife understands that 90% of dogs and cats with cancer go untreated because of unrealistically high costs associated with treatments as well as the dramatic suffering typical of treating pets with toxic, conventional chemotherapy
12
Marketing Plan
PetLife will deliver its nutraceutical and prescription strength medicines to the enormous population of untreated animals by making the product affordable and convenient in both the home and veterinary setting. PetLife will also capitalize on the increased willingness of pet owners to spend more on their animals’ preventative health, and of veterinarians to meet that demand as key drivers of this market. PetLife will also dedicate their marketing efforts to include educating the public as to the risk their companion animal has at developing cancer. The Company will emphasize the importance on pet owners being proactive and taking the necessary steps to protect their animal. The Company will offer VitalzulTM as the preventative solution.
Currently, apart from surgery which carries its own risks for older pets, the preponderance of treatment for dogs and cats with cancer is simply the same, drastically expensive (most pets do not have medical insurance), toxic chemotherapy drugs developed for humans — scaled down in dosage by the pet’s weight — with many of the same side effects such as nausea, diarrhea, lost appetite, cachexia (“wasting” loss of muscle and fat tissues) headache, hair loss, liver and kidney toxicity and susceptibility to opportune infections.
Direct Sales
PetLife has lined up key team members to execute a traditional, multichannel marketing campaign. This campaign, composed of the traditional five “P” marketing mix will include:
| ● | Product – PetLife will capitalize on the proprietary nature of their primary product offering, Vitalzul™. PetLife will sell Vitalzul™ to veterinarians using multiple respected veterinarian centers of influence to promote the product. PetLife will also sell directly to pet owners through online and brick and mortar establishments; this will be achieved using a well-connected sales force to market to both distributors and direct to retail outlets. | |
| ● | Physical attributes – a newly redesigned bottle has been approved. | |
| ● | Place or distribution – the Company will configure its corporate structure to accommodate the most efficient global supply chain, production and distribution through regional sales centers. PetLife representatives will manage the supply chain, local final production (as required) and distribution. | |
| ● | Promotion – direct to vet, direct to consumer, direct to wholesaler; there will also be trade shows, direct vet outreach and online webinars. PetLife will also implement an aggressive online marketing campaign to drive sales in the United States and key international markets using: |
| (i) | DOSEP Campaign: DOSEP (Direct Organic Search Engine Optimization) is a groundbreaking online awareness campaign and technology that will push PetLife’s web presence to the top of Google organic search results for targeted search keywords determined by PetLife management. | |
| (ii) | Multi-Touch Facebook Campaign: The retained Marketing Company will execute a targeted multi-touch Facebook advertising campaign that will generate major social awareness (and resulting online sales) of Vet Oncology products. The marketing messages will appear directly in the Facebook newsfeeds of specific demographic groups who additionally have expressed personal or professional interest in cancer treatment, based on research and targeting of the specific interests contained in their Facebook profiles. | |
| (iii) | Scientifically-Optimized Banner Ad Campaign: The Marketing Company will conduct research for optimal placement, and perform continuous split testing of ads to quickly determine “winners” and then further refine campaigns to determine the optimal combination of performance metrics to justify increasing ad budget spend for top-performing banner campaigns. |
| ● | Media – the Company will engage a top notch boutique public relations firm to generate media coverage for its products in general news, family, pet and veterinarian publications, e-zines, videos and the blogosphere to communicate Vitalzul™ features and benefits to consumers. |
13
The online strategic marketing campaigns will repeatedly “local-launch” PetLife into specific metro markets while concurrently building PetLife’s overall brand and marketing presence globally. Repeating the online marketing campaign in each additional targeted metro market will not only localize and establish the PetLife’s brand and products, each event will also catalyze PetLife’s local and nationwide Google search rankings via DOSEP, Multi-Touch Facebook and Scientifically-Optimized Banner Ads, producing both short- and long-term online sales growth, and firmly establish PetLife as a market leader.
Direct Response: Infomercials
This year an estimated $150 billion dollars in product sales will be generated by infomercials. Specifically, over $1.5 billion will be spent on pet-related purchases through infomercials. Research has shown that retail sales driven by infomercials all range from two to 15 times the infomercial sales. More and more major brands are integrating infomercials into their marketing mix. Infomercials share the product story and benefits with millions of additional prospects at a cost per lead or cost per order that usually matches or beats other direct marketing channels such as direct mail or print ads.
PetLife through its exclusive agreement with Nugget Enterprises plans to partner with a well-known household name from Hollywood and a well-respected veterinarian to film differentiated 2 to 30 minute infomercials on Vitalzul™. PetLife anticipates the infomercial will:
| ● | Reach millions of new customers and present a complete product story. | |
| ● | Enhance, support, and fill in where other advertising avenues, particularly spot television, leaves off. | |
| ● | Generate qualified leads. | |
| ● | Reduce advertising costs per order and avoid print and mailing costs. | |
| ● | Rapidly and cost-effectively introduce a new product or revive an under-marketed but potentially profitable product. |
PetLife intends to capitalize on the lucrative channels of distribution available to an infomercial marketer. Only one out of every 100 consumers watching an infomercial actively calls an 800 number and purchases the product immediately. Therefore, the retail channel provides a means for the other 99 individuals - who may have been primed by the infomercial - to buy the product.
One-step infomercials are commonly utilized for products previously unable to get retail shelf space in order to gain retailers attention and establish instant distribution. For example, PetLife can inform a retailer that more than a million consumers ordered their product directly from their television ads and thousands of others called for more information. These kinds of figures are meant to grab the attention of brick and mortar retailers, who then purchase and showcase infomercial products realizing that “as seen on TV” are big sellers at retail.
Competition
For most of the products the Company offers there are a number of competitors, several of which are publically traded where they not only manufacture and produce their own products but also have established distribution and sales networks and participate in large group purchasing organizations within the medical industry. As mature companies, they also have extensive legacy systems and expensive administrative and sales commission cost structures. In addition, there are independent distributorships of pet medications primarily focused on limited geographic markets and products located across the United States.
14
Key among the Company’s competitors are:
| ● | Paccal Vet: Paccal Vet®-CA1 has been granted conditional approval by the FDA for the treatment of: non-resectable stage III, IV or V mammary carcinoma in dogs that have not received previous chemotherapy, or radiotherapy and resectable and non-resectable squamous cell carcinoma in dogs that have not received previous chemotherapy, or radiotherapy. | |
| ● | Palladia: The only drug fully approved by the FDA for the treatment of cancer in canines is Palladia. Palladia is a prescription-only therapy is used to treat grade II or III recurrent cutaneous mast cell tumors with or without regional lymph node involvement. It works by blocking the activity of key receptors important in the development of blood vessels that supply tumors, as well as receptors vital for tumor survival | |
| ● | Zoetis, Inc.: the world’s largest producer medicine and vaccinations for pets and livestock. Zoetis is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. It offers a diversified product portfolio, including vaccines, parasiticides, anti-infectives, medicated feed additives and other pharmaceuticals, for both livestock and companion animal customers. | |
| ● | Merial, Inc.: Sanofi Pasteur is a worldwide leader in the vaccine industry. Its net sales amounted to €3,716 million in 2013, with leading vaccines in five areas: pediatric vaccines, influenza vaccines, adult and adolescent booster vaccines, meningitis vaccines, and travel and endemic vaccines. The company’s Animal Health activity is carried out through Merial, one of the world’s leading animal healthcare companies, dedicated to the research, development, manufacture and delivery of innovative pharmaceuticals and vaccines used by veterinarians, farmers and pet owners and providing a comprehensive line of products to enhance the health, well-being and performance of a wide range of production and companion animals. | |
| ● | Virbac Sa: Virbac SA develops, manufactures, and sells vaccines and medicines to prevent and treat pathologies for companion and food-producing animals in France, the rest of Europe, North America, Latin America, Africa, the Middle East, Asia, and the Pacific region. The company’s products are comprised of a multitude of products in the animal health sector. | |
| ● | Dechra Pharmaceuticals Plc: Dechra Pharmaceuticals PLC is engaged in the development, manufacture, distribution, sale, and marketing of veterinary pharmaceuticals worldwide. It markets and sells licensed branded pharmaceuticals and specialist pet foods to the veterinary professionals in Europe, as well as manufactures products for third party customers. The company also markets and sells a range of endocrine, ophthalmic, dermatological, and equine products in North America. In addition, it develops and licenses its branded veterinary product portfolio of novel and generic pharmaceuticals, and specialist pet diets. |
15
In addition to drug companies, Petlife competes with animal supplements companies. That segment is fragmented, and is dominated by small firms. However, it is witnessing tremendous growth due to the following trends;
● Pet owners view supplements as natural ways to promote health and wellness
● Veterinarians have come to view supplements as reasonable alternatives to animal drugs and are more willing to recommend them as adjuvant or even replacement therapy
● Well formulated supplements with functional ingredients that target specific physiological—and psychological—needs of today’s pets are enticing a whole population of pet parents committed to optimizing the quality of their animals’ lives
● The marketing of recognizable label claims and ingredients found in human diets, such as chicken fillets or fresh salmon, glucosamine, omega 3 fatty acids, probiotics and antioxidants attract shoppers who want to provide the “best” for their pets.
Some fast emerging companies in this field include:
● Bimini: Bimini was founded by scientists who wanted to provide pet parents with high quality, unique supplements to support the health of their dogs and cats and the proper function of their organs. The company produces treats and supplements made with human grade ingredients and are all organic, low fat, gluten, soy and corn free.
● Hyalogic: Hyalogic offers nutritional supplements based on Hyaluronic acid. The products are produced for joint care in companion animals. The company claims their supplements keep dogs active and healthy longer.
● Biozyme, INC: BioZyme® Incorporated is an innovative company in the agricultural fields of livestock nutrition and animal microbiology. Supplement brands include; Amaferm®, Sure Champ ®, Concept-Aid® and the company is expanding its supplement division to focus on research and development of products for commercial swine and poultry operations.
Intellectual Property
PetLife’s licensed patent addresses the activities associated with the “polarization” of the scorpion venom solution in order to enhance the targeted delivery to the specific cancerous cells in the dogs and cats. Additional continuation patents will be prepared that more aggressively address the efficacy of the Polarized Blue Scorpion venom for pets and livestock. The next continuation of the patent is anticipated to be Vitalzul GNP-1™, which is the drug version and will be the polarization of gold nanoparticles in combination with Blue Scorpion Venom. Medolife has already engaged a group of intellectual property professionals (Hankin Patent Law) specifically skilled in the bio-pharmaceutical areas associated with the Vitalzul™ product.
PetLife intends to establish qualified distribution arrangements in strategic countries within 12 months of starting US nutraceutical distribution. The procedural activities associated with the introduction of Vitalzul ™ as an accepted nutraceutical and drug in a foreign country can be technically demanding. Achieving the desired expansion of the company’s international licensing campaign will require the addition of staff including international legal experts, processing personnel and operationally focused digital support systems.
Regulatory Issues
There are worldwide, national, state and local rules, regulations and statutes that may impact the Company’s ability to fully implement our strategic plan. The sale of animal health products is governed by the laws and regulations specific to each country in which we sell our products. To maintain compliance with these regulatory requirements, we have established processes, systems and dedicated resources with involvement from product concept to launch and maintenance in the market. In the majority of our markets, the relevant animal health authority is separate from those governing human medicinal products.
16
United States
The regulatory body that is responsible for the regulation of animal health pharmaceuticals in the United States is the Center for Veterinary Medicine (CVM), housed within the United States Food and Drug Administration (FDA). All manufacturers of animal health pharmaceuticals must show their products to be safe, effective and produced by a consistent method of manufacture as defined under the Federal Food, Drug and Cosmetic Act. Post-approval monitoring of products is required by law, with reports being provided to the CVM’s Surveillance and Compliance group. Reports of product quality defects, adverse events or unexpected results are produced in accordance with the law. Additionally, we are required to submit all new information for a product, regardless of the source.
The regulatory body in the United States for veterinary vaccines is the United States Department of Agriculture (USDA). The USDA’s Center for Veterinary Biologics is responsible for the regulation of animal health vaccines, including immunotherapeutics. All manufacturers of animal health biologicals must show their products to be pure, safe, effective and produced by a consistent method of manufacture as defined under the Virus Serum Toxin Act. Post-approval monitoring of products is required. Reports of product quality defects, adverse events or unexpected results are produced in accordance with the agency requirements.
Outside of the United States
Country-specific regulatory laws have provisions that include requirements for certain labeling, safety, efficacy and manufacturers’ quality control procedures (to assure the consistency of the products), as well as company records and reports. With the exception of the European Union, most other countries’ regulatory agencies will generally refer to the FDA, USDA, EU and other international animal health entities, including the World Organization for Animal Health, Codex Alimentarius, in establishing standards and regulations for veterinary pharmaceuticals and vaccines.
Employees
Currently, we have five employees, of which three are executive officers. We have good relationships with our employees and do not anticipate issues relative to our employees.
Properties
We presently lease our principal executive offices, located at 38 West Main Street, Hancock, MD 20715. We believe that our present business property is adequate and suitable to meet our needs.
The PetLife Scorpion Reservation is located in a remote hill area approximately 4 hours driving time from Santo Domingo, the capital of the Dominican Republic. The farm includes approximately 50,000 square meters (12 acres) of land of which 60% is usable for scorpion habitat. PetLife currently has access to 41,500 scorpions with the potential post funding capacity for up to one million scorpions. PetLife can currently produce 500,000 units of VitalzulTM per month.
Strategically, Medolife is looking to increase the size of its Scorpion Reservation in order to allow for a reduction in the scorpion density per population unit as well as build an onsite state of the art laboratory which will also house the scorpion milking center and interior scorpion breeding and habitat to provide production insurance against unanticipated weather / environmental catastrophes. The reservation will be managed by PetLife specialists including handlers, milkers, biologists and reservation managers.
17
Medolife, has an alliance with Laboratório de Artrópodes, Instituto Butantan in Sao Paolo, Brazil. Instituto Butanan are experts in the maintenance and breeding of Scorpions. They have 20 years of experience and are willing to share their experience and methodology of Scorpion maintenance and breeding with PetLife. They have been using the Scorpion venom effectively for the production of a Scorpion antidote medication. PetLife will implement their 20 years of experience to ensure an efficient scorpion maintenance and breeding operation.
PetLife also anticipates working with global venom research leaders such as Venomics (a French Government funded research group of companies from five European Union countries) and Venomtech (Specialists in Venom technology) in France, to ensure the latest research is utilized to ensure the most effective results from PetLife’s products. PetLife will also utilize the results and benefits from other venom based research and approved products; for example, the FDA approved scorpion antidote, Anascorp.
Legal Proceedings
We are not currently a party in any legal proceeding or governmental regulatory proceeding nor are we currently aware of any pending or potential legal proceeding or governmental regulatory proceeding proposed to be initiated against us.
Our business and an investment in our securities are subject to a variety of risks. The following risk factors describe some of the most significant events, facts or circumstances that could have a material adverse effect upon our business, financial condition, results of operations, ability to implement our business plan and the market price for our securities. Many of these events are outside of our control. If any of these risks actually occurs, our business, financial condition or results of operations may be materially adversely affected. In such case, the trading price of our common stock could decline and investors in our common stock could lose all or part of their investment.
Risks Related to our Business
We were formed on December 12, 2012 and have a limited operating history and accordingly may not be able to effectively operate our business.
We are still in the early stages of company development and accordingly, there is only a limited basis upon which to evaluate our prospects for achieving our intended business objectives. There can be no assurance that we will ever achieve positive cash flow or profitability, or that if either is achieved, that it will be at the levels estimated by management.
We have not yet generated any revenue to date. Our failure to generate significant revenues would seriously harm our business. Even if we are able to access capital, we anticipate that we will experience operating losses and incur significant and increasing losses in the future due to growth, expansion, development and marketing. In the event that we are able to raise adequate capital, we expect to significantly increase our sales and marketing and general and administrative expenses. As a result of these additional expenses, we would need to generate substantial revenues to become profitable. We expect to incur significant operating losses for at least the next several years.
18
Our independent auditors have expressed substantial doubt about our ability to continue as a going concern, which may hinder our ability to obtain future financing.
The report of our independent auditors on our consolidated financial statements for the year ended August 31, 2016 included an explanatory paragraph indicating that there is substantial doubt about our ability to continue as a going concern. Our auditors’ doubts are based on our incurring significant losses from operations and our working capital deficit position. Our ability to continue as a going concern will be determined by our ability to obtain additional funding in the short term to enable us to realize the commercialization of our planned business operations. Our consolidated financial statements do not include any adjustments that might result from the outcome of this uncertain.
Our Vitalzul ™ product has not been approved by the FDA.
U.S. pet owners may be hesitant to consider Vitalzul ™ for treating cancer without FDA approval. Alternative cancer treatments are not well-accepted in the U.S. The Company will need to educate and change the mindset of those who normally would not seek medicinal alternatives for themselves or for their pets for us to be successful. Obtaining approval for our products will be a lengthy and very costly process, the success of which cannot be assured.
Our Brand is not well known in the United States.
Marketing Vitalzul products will require the Company to establish branding reputation of credibility. U.S. pet owners and veterinarians must become familiar with the products. Due to lack of brand recognition, significant advertising budgets will be required to market and promote products in the U.S. Additional costs are required for a team of experts to seek approval of the PetLife products in foreign markets. The brand initially may not be able to position itself on price, within the natural remedies markets. While the product is less costly than chemotherapy treatments, it may still not be reasonably priced for entry in some markets.
We will require approval for the Products in Numerous Countries.
Even though Medolife products have been approved for sale in six countries, our PetLife products may not be approved. If it is not approved in the countries selected to market and promote the products, PetLife will need to consider secondary markets, which may have limited sales potential. In addition, many chemotherapy drugs used by veterinarians today are used as “off label” treatments with no FDA approval for veterinary use, regardless of successful use in treating humans. Veterinarians who have had success with these drugs may be hesitant to try something new or more natural in treating pet cancers.
19
We are highly dependent on the continued availability of our scorpion farm facilities and would be harmed if they were unavailable for any prolonged period of time.
Any failure in the physical infrastructure of our scorpion farm facilities or services could lead to significant costs and disruptions that could reduce our revenues and harm our business reputation and financial results. We are highly reliant on our Dominican Republic facilities. Any natural or man-made event that impacts our ability to utilize these facilities could have a significant impact on our operating results, reputation and ability to continue operations. Our ability to rebuild facilities would take a considerable amount of time and expense and cause a significant disruption in service to our customers.
Though PetLife sister company, Medolife, is working with venom experts from the Instituto Butantan, São Paulo, Brazil, in applying their methods and experience and knowhow to manage and grow a large population of scorpions necessary to make sufficient amounts of the product; demand for the venom may increase, particularly if nutraceutical or pharmaceutical companies decide they want to enter the market. This could decrease the availability of scorpion venom which would result in price increases for PetLife.
We are not currently profitable and we will need to raise additional funds in the future; however, additional funds may not be available on acceptable terms, or at all.
We have substantial operating expenses associated with the sales and marketing of our products. The sales and marketing expenses are anticipated to be funded from operating cash flow and from potential financing transactions. There can be no assurance that we will have sufficient access to liquidity or cash flow to meet our operating expenses and other obligations. If we do not increase our revenue or reduce our expenses, we will need to raise additional capital, which would result in dilution to our stockholders, or seek additional loans. The incurrence of indebtedness would result in increased debt service obligations and could require us to agree to operating and financial covenants that would restrict our operations. Financing may not be available in amounts or on terms acceptable to us, if at all. Any failure by us to raise additional funds on terms favorable to us, or at all, could result in our inability to pay our expenses as they come due, limit our ability to expand our business operations, and harm our overall business prospects.
We may not be able to raise capital or, if we can, it may not be on favorable terms. We may seek to raise additional capital through public or private equity financings, partnerships, joint ventures, dispositions of assets, debt financings or restructurings, bank borrowings or other sources. To obtain additional funding, we may need to enter into arrangements that require us to relinquish rights to certain technologies, products and/or potential markets. If adequate funds are not otherwise available, we would be forced to curtail operations significantly, including reducing our sales and marketing expenses which could negatively impact product sales and we could even be forced to cease operations, liquidate our assets and possibly even seek bankruptcy protection.
20
We operate in a highly regulated environment, and any legal or regulatory action could be time-consuming and costly.
If we fail to comply with all applicable laws, standards and regulations, action by the FDA or other regulatory agencies could result in significant restrictions, including restrictions on the marketing or use of our products or the withdrawal of products from the market. Any such restrictions or withdrawals could materially affect our business and operations. In addition, governmental authorities could impose fines, seize our inventory of products, or force us to recall any product already in the market if we fail to comply with governmental regulations.
Competitive products exist and more will be developed, and we may not be able to successfully compete because we are smaller and have fewer financial resources.
Our business is in a very competitive and evolving field. Rapid new developments in this field have occurred over the past few years, and are expected to continue to occur. Other companies already have competing products available or may develop products to compete with ours. Many of these products have short regulatory timeframes and our competitors, many with more substantial development resources, may be able to develop competing products that are equal to or better than ours. This may make our products obsolete or undesirable by comparison and reduce our revenue. Our success will depend, in large part, on our ability to maintain a competitive position concerning our intellectual property, and to develop new technologies and new applications for our technologies. Many of our competitors have substantially greater financial and technical resources, as well as greater production and marketing capabilities, and our ability to compete remains uncertain.
We will need to continue to innovate and develop new products to be desirable to our customers.
The markets for our products and services are characterized by rapid technological change, frequent new introductions, changes in customers’ demands and evolving industry standards. Accordingly, we will need to continue to innovate and develop additional products. These efforts can be costly, subject to long development and regulatory delays and may not result in products approved for sale. These costs may hurt operating results and may require additional capital. If additional capital is not available, we may be forced to curtail development activities. In addition, any failure on our behalf to react to changing market conditions could create an opportunity for other market participants to capture a critical share of the market within a short period of time.
Our success will depend on our ability to engage and retain qualified technical personnel who are difficult to attract.
Our success will depend on our ability to attract and retain qualified technical personnel to assist in research and development, testing, product implementation, low-scale production and technical support. The demand for such personnel is high and the supply of qualified technical personnel is limited. A significant increase in the wages paid by competing employers could result in a reduction of our technical work force and increases in the wage rates that we must pay or both. If either of these events were to occur, our cost structure could increase and our growth potential could be impaired.
21
Loss of key members of our management who we need to succeed could adversely affect our business.
We are highly dependent on the services of key members of our management team, and the loss of any of their services could have an adverse effect on our future operations. We do not currently maintain key-man life insurance policies insuring the life of any member of our management team.
We will be required to invest in facilities and equipment on a continuing basis, which will put pressure on us to finance these investments.
We have invested, and intend to continue to invest, in facilities and state-of-the-art equipment in order to increase, expand or update our capabilities and facilities. Changes in technology or sales growth beyond currently established production capabilities, which we anticipate, will require further investment. However, there can be no assurance that we will generate sufficient funds from operations to maintain our existing facilities and equipment or to finance any required capital investments or that other sources of funding will be available. Additionally, there can be no guarantee that any future expansion will not negatively affect earnings.
Future revenue will depend on our ability to increase sales.
We intend to sell our products through numerous means, including direct sales by our employees, through infomercials and through a multi-level marketing program. We have and will continue to incur increased sales and marketing expenses in building and expanding our sales force, and there can be no assurance that we will generate increased sales as a result of this effort.
Our operating results will be harmed if we are unable to effectively manage and sustain our future growth.
We might not be able to manage our future growth efficiently or profitably. Our business is unproven on a large scale and actual revenue and operating margins, or revenue and margin growth, may be less than expected. If we are unable to scale our production capabilities efficiently, we may fail to achieve expected operating margins, which would have a material and adverse effect on our operating results. Growth may also stress our ability to adequately manage our operations, quality of products, safety and regulatory compliance. In order to grow, we may be required to obtain additional financing, which may increase our indebtedness or result in dilution to our stockholders. Further, there can be no assurance that we would be able to obtain any additional financing.
22
Our success depends on our ability to avoid infringing on the intellectual property rights of third parties which could expose us to litigation or commercially unfavorable licensing arrangements.
Our commercial success depends in part on our ability to avoid infringing patents and proprietary rights of third parties. Third parties may accuse us of employing their proprietary technology in our products, or in the materials or processes used to research or develop our products, without authorization. Any legal action against us claiming damages and/or seeking to stop our commercial activities relating to the affected products, materials and processes could, in addition to subjecting us to potential liability for damages, require us to obtain a license to continue to utilize the affected materials or processes or to manufacture or market the affected products. We cannot predict whether we would prevail in any of these actions or whether any license required under any of these patents would be made available on commercially reasonable terms, if at all. If we are unable to obtain such a license, we may be unable to continue to utilize the affected materials or processes or manufacture or market the affected products or we may be obligated by a court to pay substantial royalties and/or other damages to the patent holder. Even if we are able to obtain such a license, the terms of such a license could substantially reduce the commercial value of the affected product or products and impair our prospects for profitability. Accordingly, we cannot predict whether or to what extent the commercial value of the affected product or products or our prospects for profitability may be harmed as a result of any of the liabilities discussed above. Furthermore, infringement and other intellectual property claims, with or without merit, can be expensive and time-consuming to litigate and can divert management’s attention from our core business. We may be unable to obtain and enforce intellectual property rights to adequately protect our products and related intellectual property.
Our business will become subject to continuing regulatory compliance by the FDA and other authorities which is costly and could result in delays in the commercialization of our products.
Upon completion of the FDA process for our approved drug Escozine for Pets product, we will become subject to extensive regulation by the FDA and potentially other federal governmental agencies and, in some jurisdictions, by state and foreign governmental authorities. These regulations govern the introduction of new pharmaceuticals even for pets, the observance of certain standards with respect to the design, manufacture, testing, labeling, promotion and sales of the pharmaceuticals, the maintenance of certain records, the ability to track devices, the reporting of potential problems, and other matters.
Future revenue will depend on our ability to develop new sales channels and there can be no assurance that these efforts will result in significant revenues.
We are heavily dependent on developing sales channels for our products but there can be no assurance that these channels can be developed or that we will continue to be successful in selling our products. We are engaging in a major initiative to build and further expand our direct sales force, as well as develop infomercial and multi-level marketing sales. This effort will have significant costs that will be incurred prior to the generation of revenue sufficient to cover these costs. The costs incurred for these efforts may impact our operating results and there can be no assurance of their effectiveness. Many of our competitors have well-developed sales channels and it may be difficult for us to break through these competitors to take market share. If we are unable to develop these sales channels, we may not be able to grow revenue or maintain our current level of revenue generation.
23
Risks Related to our Stock
There may be fluctuations in our operating results, which will impact our stock price.
Significant annual and quarterly fluctuations in our results of operations may be caused by, among other factors, our volume of revenues, the timing of new product or service announcements, releases by us and our competitors in the marketplace of new products or services, seasonality and general economic conditions. There can be no assurance that the level of revenues achieved by us in any particular fiscal period will not be significantly lower than in other comparable fiscal periods. Our expense levels are based, in part, on our expectations as to future revenues. As a result, if future revenues are below expectations, net income or loss may be disproportionately affected by a reduction in revenues, as any corresponding reduction in expenses may not be proportionate to the reduction in revenues.
Because we became public through a reverse merger, we may not be able to attract the attention of major brokerage firms or certain investors.
There are coverage risks associated with our becoming public through a reverse merger, including, among other things, security analysts of major brokerage firms may not provide coverage of us since there is no incentive to brokerage firms to recommend the purchase of our common stock. In addition, we may not attract the attention of major brokerage firms and certain investors due to the possibility of a low stock price. We cannot assure you that brokerage firms would want to conduct any public offerings on our behalf in the future.
The market price of our common stock is extremely volatile, which may affect our ability to raise capital in the future and may subject the value of your investment to sudden decreases.
The market price for securities of biotechnology companies, including ours, historically has been highly volatile, and the market from time to time has experienced significant price and volume fluctuations that are unrelated to the operating performance of such companies. Fluctuations in the trading price or liquidity of our common stock may harm the value of your investment in our common stock.
Our stockholders may experience significant dilution if future equity offerings are used to fund operations or acquire complementary businesses.
If our future operations or acquisitions are financed through the issuance of equity securities, our stockholders could experience significant dilution. In addition, securities issued in connection with future financing activities or potential acquisitions may have rights and preferences senior to the rights and preferences of our common stock.
We do not anticipate paying dividends in the foreseeable future; you should not buy our stock if you expect dividends.
We currently intend to retain our future earnings to support operations and to finance expansion and, therefore, we do not anticipate paying any cash dividends on our common stock in the foreseeable future.
24
Our current management can exert significant influence over us and make decisions that are not in the best interests of all stockholders.
As of August 31, 2016, our executive officers and directors beneficially owned as a group approximately 13.9% of our outstanding shares of common stock. These officers continue to own a controlling interest in the stock. As a result, these stockholders will be able to assert significant influence over all matters requiring stockholder approval, including the election and removal of directors and any change in control. In particular, this concentration of ownership of our outstanding shares of common stock could have the effect of delaying or preventing a change in control, or otherwise discouraging or preventing a potential acquirer from attempting to obtain control. This, in turn, could have a negative effect on the market price of our common stock. It could also prevent our stockholders from realizing a premium over the market prices for their shares of common stock. Moreover, the interests of the owners of this concentration of ownership may not always coincide with our interests or the interests of other stockholders and, accordingly, could cause us to enter into transactions or agreements that we would not otherwise consider.
Our common stock is considered “penny stock” and may be difficult to sell.
The SEC has adopted Rule 3a51-1, which establishes the definition of a “penny stock” for the purposes relevant to us, as any equity security that has a market price of less than $5.00 per share or with an exercise price of less than $5.00 per share, subject to certain exceptions. The market price of our common stock is less than $5.00 per share and therefore may be designated as a “penny stock” according to SEC rules. For any transaction involving a penny stock, unless exempt, Rule 15g-9 requires:
● that a broker or dealer approve a person’s account for transactions in penny stocks; and
● that the broker or dealer receives from the investor a written agreement to the transaction, setting forth the identity and quantity of the penny stock to be purchased.
In order to approve a person’s account for transactions in penny stocks, the broker or dealer must:
● obtain financial information and investment experience objectives of the person; and
● make a reasonable determination that the transactions in penny stocks are suitable for that person and the person has sufficient knowledge and experience in financial matters to be capable of evaluating the risks of transactions in penny stocks. The broker or dealer must also deliver, prior to any transaction in a penny stock, a disclosure schedule prescribed by the SEC relating to the penny stock market, which, in highlight form:
● sets forth the basis on which the broker or dealer made the suitability determination; and
● that the broker or dealer received a signed, written agreement from the investor prior to the transaction.
25
Disclosure also has to be made about the risks of investing in penny stocks in both public offerings and in secondary trading and about the commissions payable to both the broker-dealer and the registered representative, current quotations for the securities and the rights and remedies available to an investor in cases of fraud in penny stock transactions. Finally, monthly statements have to be sent disclosing recent price information for the penny stock held in the account and information on the limited market in penny stocks.
Generally, brokers may be less willing to execute transactions in securities subject to the “penny stock” rules. This may make it more difficult for investors to dispose of our Common Stock and cause a decline in the market value of our stock. In addition, since the Common Stock is currently traded on the OTC Bulletin Board, investors may find it difficult to obtain accurate quotations of the Common Stock and may experience a lack of buyers to purchase such stock or a lack of market makers to support the stock price.
We could issue “blank check” preferred stock without stockholder approval with the effect of diluting then current stockholder interests and impairing their voting rights, and provisions in our charter documents and under Nevada law could discourage a takeover that stockholders may consider favorable.
Our certificate of incorporation provides for the authorization to issue up to 50,000,000 shares of “blank check” preferred stock with designations, rights and preferences as may be determined from time to time by our board of directors. Our board of directors is empowered, without stockholder approval, to issue one or more series of preferred stock with dividend, liquidation, conversion, voting or other rights which could dilute the interest of, or impair the voting power of, our common stockholders. The issuance of a series of preferred stock could be used as a method of discouraging, delaying or preventing a change in control. For example, it would be possible for our board of directors to issue preferred stock with voting or other rights or preferences that could impede the success of any attempt to change control of our company.
Item 1B. Unresolved Staff Comments
Not applicable
Properties
We presently lease our principal executive offices, located at 38 West Main Street, Hancock, MD 21750. We believe that our present business property is adequate and suitable to meet our needs.
The PetLife Scorpion Reservation, owned and maintained by Medolife, an affiliated company through common ownership, is located in a remote hill area approximately 4 hours driving time from Santo Domingo, the capital of the Dominican Republic. The farm includes approximately 50,000 square meters (12 acres) of land of which 60% is usable for scorpion habitat. Through an agreement with Medolife, Petlife currently has access to 41,500 scorpions with the potential post funding capacity for up to one million scorpions and can currently produce 500,000 units of Escozine for Pets per month.
26
Strategically, Medolife is looking to increase the size of its Scorpion Reservation in order to allow for a reduction in the scorpion density per population unit as well as build an onsite state of the art laboratory which will also house the scorpion milking center and interior scorpion breeding and habitat to provide production insurance against unanticipated weather / environmental catastrophes. The reservation will be managed by Medolife specialists including handlers, milkers, biologists and reservation managers.
Medolife, has an alliance with Laboratório de Artrópodes, Instituto Butantan in Sao Paolo, Brazil. Instituto Butanan are experts in the maintenance and breeding of Scorpions. They have 20 years of experience and are willing to share their experience and methodology of Scorpion maintenance and breeding with Medolife. They have been using the Scorpion venom effectively for the production of a Scorpion antidote medication. Medolife will implement their 20 years of experience to ensure an efficient scorpion maintenance and breeding operation.
PetLife also anticipates working with global venom research leaders such as Venomics (a French Government funded research group of companies from five European Union countries) and Venomtech (Specialists in Venom technology) in France, to ensure the latest research is utilized to ensure the most effective results from PetLife’s products. PetLife will also utilize the results and benefits from other venom based research and approved products; for example, the FDA approved scorpion antidote, Anascorp.
We are not currently a party in any legal proceeding or governmental regulatory proceeding nor are we currently aware of any pending or potential legal proceeding or governmental regulatory proceeding proposed to be initiated against us.
Item 4. Mine Safety Disclosures
Not applicable.
27
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
Trading Information
Our common stock trades in the over-the-counter market and is currently quoted on the OTCQB maintained by OTC Markets Group, Inc. under the symbol PTLF.
Below is a table indicating the range of high and low closing price information for the common stock as reported by the OTC Markets Group for the periods listed. These prices do not necessarily reflect actual transactions.
| High | Low | |||||||
| Through December 13, 2016 | $ | 0.80 | $ | 0.30 | ||||
| August 31, 2016 | 1.00 | 0.0202 | ||||||
| May 31, 2016 | 0.3111 | 0.02 | ||||||
| February 29, 2016 | 0.253 | 0.03 | ||||||
| High | Low | |||||||
| Through December 13, 2015 | $ | 0.35 | $ | 0.08 | ||||
| August 31, 2015 | 0.43 | 0.08 | ||||||
| May 31, 2015 | 1.00 | 0.16 | ||||||
| February 28, 2015 | 2.25 | 0.13 | ||||||
Transfer Agent
Our current transfer agent and registrar for our common stock is Empire Stock Transfer, 1859 Whitney Mesa Drive, Henderson, NV 89014.
As of August 31, 2016, there were 132 reported holders of record of our common stock and a total of 8,399,422 shares of Common Stock issued and outstanding.
We have never paid a cash dividend. Payment of future dividends, if any, will be at the discretion of our Board of Directors after taking into account various factors, including the terms of any credit arrangements, our financial condition, operating results, current and anticipated cash needs and plans for growth. Our initial earnings, if any, will likely be retained to finance our growth. At the present time, we are not party to any agreement that would limit our ability to pay dividends.
28
The Securities Enforcement and Penny Stock Reform Act of 1990
The Securities and Exchange Commission has adopted rules that regulate broker-dealer practices in connection with transactions in penny stocks. Penny stocks are generally equity securities with prices of less than $5.00 (other than securities registered on certain national securities exchanges or quoted on the NASDAQ system, provided that current prices and volume information with respect to transactions in such securities is provided by the exchange or system). Our shares are currently subject to the penny stock rules.
A purchaser is purchasing penny stock which limits the ability to sell the stock. The classification of penny stock makes it more difficult for a broker-dealer to sell the stock into a secondary market, which makes it more difficult for a purchaser to liquidate his/her investment. Any broker-dealer engaged by the purchaser for the purpose of selling his or her shares in us will be subject to Rules 15g-1 through 15g-10 of the Securities and Exchange Act. Rather than creating a need to comply with those rules, some broker-dealers will refuse to attempt to sell penny stock.
The penny stock rules require a broker-dealer, prior to a transaction in a penny stock not otherwise exempt from those rules, to deliver a standardized risk disclosure document prepared by the Commission, which:
| ● | contains a description of the nature and level of risk in the market for penny stocks in both public offerings and secondary trading; |
| ● | contains a description of the broker’s or dealer’s duties to the customer and of the rights and remedies available to the customer with respect to a violation to such duties or other requirements of the Securities Act of 1934, as amended; |
| ● | contains a brief, clear, narrative description of a dealer market, including “bid” and “ask” prices for penny stocks and the significance of the spread between the bid and ask prices; |
| ● | contains a toll-free telephone number for inquiries on disciplinary actions; |
| ● | defines significant terms in the disclosure document or in the conduct of trading penny stocks; and |
| ● | contains such other information and is in such form (including language, type, size and format) as the Securities and Exchange Commission shall require by rule or regulation. |
| ● | The broker-dealer also must provide, prior to effecting any transaction in a penny stock, to the customer: |
| ● | the bid and offer quotations for the penny stock; |
| ● | the compensation of the broker-dealer and its salesperson in the transaction; |
| ● | the number of shares to which such bid and ask prices apply, or other comparable information relating to the depth and liquidity of the market for such stock; and |
| ● | monthly account statements showing the market value of each penny stock held in the customer’s account. |
In addition, the penny stock rules require that prior to a transaction in a penny stock not otherwise exempt from those rules; the broker-dealer must make a special written determination that the penny stock is a suitable investment for the purchaser and receive the purchaser’s written acknowledgment of the receipt of a risk disclosure statement, a written agreement to transactions involving penny stocks, and a signed and dated copy of a written suitability statement. These disclosure requirements have the effect of reducing the trading activity in the secondary market for our stock. Thus, stockholders may have difficulty selling their securities.
29
Securities Authorized for Issuance under Equity Compensation Plans
Equity Compensation Plan Information
The following sets forth information for the equity compensation plans outstanding as of August 31, 2016 (including individual compensation arrangements) under which shares of our common stock are authorized for issuance:
Equity Compensation Plan Information
| Number of securities | ||||||||||
| to be issued upon | Weighted average | Number of securities | ||||||||
| exercise of | exercise price of | remaining available for | ||||||||
| outstanding options, | outstanding options, | future issuance as of | ||||||||
| Plan Category | warrants and rights | warrants and rights | August 31, 2016 | |||||||
| Equity compensation plans approved by security holders: | - | - | - | |||||||
| Equity compensation plans not approved by security holders: | 4,000,000 | $ | 0.25 | - | ||||||
30
Item 6. Selected Financial Data.
Not required by smaller reporting companies.
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following discussion provides information that management believes is relevant to an assessment and understanding of the financial condition and results of operations of Petlife Pharmaceuticals, Inc).
This discussion addresses matters we consider important for an understanding of our financial condition and results of operations for the years ended August 31, 2016 and 2015. It consists of the following subsections:
“Introduction and Plan of Operation” which provides a brief summary of our consolidated results and financial position and the primary factors affecting those results, as well as a summary of our expectations for fiscal 2017;
“Liquidity and Capital Resources,” which contains a discussion of our cash flows and liquidity, investing activities and financing activities, contractual obligations, and critical obligations;
“Results of Operations and Comparison”,” which sets forth an analysis of the operating results for the last two fiscal years
Critical Accounting Policies,” which provides an analysis of the accounting policies we consider critical because of their effect on the reported amounts of assets, liabilities, income and/or expenses in our consolidated financial statements and/or because they require difficult, subjective or complex judgments by our management;
“Recent Accounting Pronouncements and Developments,” which summarizes recently published authoritative accounting guidance, how it might apply to us and how it might affect our future results.
This item should be read in conjunction with our consolidated financial statements and the notes thereto included in this annual report.
31
Introduction and Plan of Operation
The following discussion updates our plan of operation for the 2016 Fiscal Year. The discussion also summarizes the results of our operations for the years ended August 31, 2016 and 2015.
Merger Agreements
On July 20, 2016, Petlife Pharmaceuticals, Inc. entered into an Agreement and Plan of Merger with its wholly-owned subsidiary, PetLife Merger Subsidiary, Inc., a Nevada Corporation, with PetLife Merger Subsidiary, Inc. being the surviving entity. As part of that merger, the name of the Petlife Merger Subsidiary was changed back to PetLife Pharmaceuticals, Inc. The purpose of the subsidiary merger was to effectuate a 1 for 5 reverse exchange of Petlife’s common stock pursuant to the terms of the merger. The combined entities continue on public markets pursuant to Rule 12g-3 of the Securities Exchange Act of 1934, as amended.
Plan of Operations
For the years ended August 31, 2016 and 2015, we experienced the negative effects of the financial markets upheaval, which made capital acquisition extremely difficult.
We will be developing nutraceuticals and FDA approved prescription drugs for veterinary use for retail sales and distribution throughout the world.
About Petlife Pharmaceuticals, Inc.
PetLife Pharmaceuticals, Inc. (PetLife) has developed and is launching a new generation of potentiated veterinary cancer medications and nutraceuticals, based on the same patented formula “Escozine” and production processes that have been scientifically proven as an effective treatment for cancer in humans for years. Escozine (for humans) is currently sold as either a nutraceutical or prescription drug in 40 countries including the United States.
Petlife’s primary goal is to bring its scientifically proven, potentiated bioactive medication and Nutraceuticals to the world of veterinary oncology, with the ultimate goal of extending the life of pets with cancer and improving their quality of life. In the process of achieving these objectives, Petlife will transition into a world renowned, professionally respected veterinary pharmaceutical company that will create new industry standards as well as being profitable and innovative.
Results of Operations
Year ended August 31, 2016 compared to period ended August 31, 2015
Operating expenses
For the year ended August 31, 2016 we incurred $3,687,040 in operating expenses as compared to $1,932,201 in operating expenses we incurred for the prior year primarily due to increased stock-based compensation from $1,549,640 to $3,051,374.
32
Operating loss
For the year ended August 31, 2016 we incurred a loss from operations of $3,687,040 as compared to the operating loss we incurred for the year ended August 31, 2015 of $1,932,201.
Net loss
We incurred a net loss of $3,687,040 for the year ended August 31, 2016 as compared to the net loss we incurred for the year ended August 31, 2015 of $1,932,201. The increase in net loss is attributable principally to increased stock-based compensation.
Liquidity and Capital Resources
The Company has been in the development stage and received no revenue from business operations for the years ended August 31, 2016 and 2015. We have consequently relied on funds received in connection with our equity and debt offerings to finance our ongoing operations. We have experienced net losses since inception, and we expect we will continue to incur losses for the next year. As of the date of this filing, we do not have any available external source of funds. We require additional capital in the near term to maintain our current operations. Although we are actively seeking additional equity and debt financing, such financing may not be available on acceptable terms, if at all.
Our consolidated financial statements have been prepared assuming that we will continue as a going concern. Since our inception on December 12, 2012, we have not generated revenue and have incurred net loss. Accordingly, we have not generated cash flow from operations and have primarily relied upon loans from officers, promissory notes and advances from related parties, and equity financing to fund our operations. The report of our Independent Registered Public Accounting Firm include an explanatory paragraph indicating that there is substantial doubt about our ability to continue as a going concern.
We do not have sufficient cash resources or current assets to pay our obligations, and we have been meeting many of our obligations through the issuance of our common stock to our employees, consultants and advisors as payment for goods and services. Considering the foregoing, we are dependent on additional financing to continue our operations. Our significant capital requirements for the foreseeable future include development and operational costs, and our corporate overhead expenses.
We are actively seeking additional equity or debt financing. However, there can be no assurance that funds required during the next twelve months or thereafter will be available from external sources. The lack of additional capital resulting from the inability to generate cash flow from operations or to raise capital from external sources would force us to substantially curtail or cease operations and would, therefore, have a material adverse effect on our business. Further, there can be no assurance that any such required funds, if available, will be available on attractive terms or that they will not have a significantly dilutive effect on our existing shareholders. All of these factors have been exacerbated by the extremely unsettled credit and capital markets presently existing.
33
Net Cash Used in Operating Activities
Net cash used in operating activities was $151,839 for the year ended August 31, 2016, as compared to net cash used of $22,034 in prior year’s operating activities. The increase was primarily due to the increase in net loss as compared to the activity incurred in 2015.
Net Cash Used in Investing Activities
The Company used $0 for investing for the year end August 31, 2016. For the year end August 31, 2015 the Company used $600 for capital expenditures.
Net Cash Provided by Financing Activities
During the year ended August 31, 2016, we received net cash provided by financing activities totaling $153,011 from a loan from officer. During the year ended August 31, 2015, we received net cash provided by financing activities totaling $15,782 from a shareholder advance and due from affiliate.
Going Concern
The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has not established any sources of revenue to cover its operating expenses for the years ended August 31, 2016 and 2015. In addition, the Company has incurred accumulated deficit of approximately $7,000,000 and used $151,839 in cash for operating activities for the year ended August 31, 2016. These factors raise substantial doubt about the Company’s ability to continue as a going concern.
The Company’s ability to continue existence is dependent upon commencing its planned operations, management’s ability to develop and achieve profitable operations and/or upon obtaining additional financing to carry out its planned business. The Company intends to fund its business development, acquisition endeavors and operations through equity and debt financing arrangements.
There can be no assurance that any additional financings will be available to the Company on satisfactory terms and conditions, if at all. In the event the Company is unable to continue as a going concern, it may elect or be required to seek protection from its creditors by filing a voluntary petition in bankruptcy or may be subject to an involuntary petition in bankruptcy. To date, management has not considered this alternative, nor does management view it as a likely occurrence.
The accompanying consolidated financial statements do not include any adjustments related to the recoverability or classification of asset-carrying amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.
34
Critical Accounting Policies and Estimates
Estimates
The preparation of the financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates.
Cash
The Company considers cash to consist of cash on hand and temporary investments having an original maturity of 90 days or less that are readily convertible into cash.
Property and Equipment
Property and equipment are stated at cost. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings.
Income Taxes
The Company has adopted Accounting Standards Codification subtopic 740-10, Income Taxes (“ASC 740-10”) which requires the recognition of deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the financial statement or tax returns. Under this method, deferred tax liabilities and assets are determined based on the difference between financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Temporary differences between taxable income reported for financial reporting purposes and income tax purposes consist primarily of timing differences such as deferred officers’ compensation and stock based compensation accounting.
Net Loss per Common Share, basic and diluted
The Company has adopted Accounting Standards Codification subtopic 260-10, Earnings Per Share (“ASC 260-10”) specifying the computation, presentation and disclosure requirements of earnings per share information. Basic loss per share has been calculated based upon the weighted average number of common shares outstanding.
Stock based compensation
The Company follows Accounting Standards Codification subtopic 718-10, Compensation (“ASC 718-10”) which requires that all share-based payments to both employees and non-employees be recognized in the income statement based on their fair values.
35
Concentrations of Credit Risk
Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash, cash equivalents and trade receivables. The Company places its cash and temporary cash investments with high credit quality institutions. At times, such investments may be in excess of the FDIC insurance limit.
Research and Development
The Company accounts for research and development costs in accordance with Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved as defined under the applicable agreement. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company incurred costs of $0 and $0 for research and development for the years ended August 31, 2016 and 2015.
Fair Value
Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”) requires disclosure of the fair value of certain financial instruments. The carrying amount reported in the unaudited condensed consolidated balance sheet for accounts payable and accrued expenses, advances and notes payable approximates fair value because of the immediate or short-term maturity of these financial instruments.
Recent Accounting Pronouncements
In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers (Topic 606).” This guidance outlines a single, comprehensive model for accounting for revenue from contracts with customers. We will adopt the standard in 2018. While we are currently assessing the impact of the new standard, we do not expect this new guidance to have a material impact on our Consolidated Financial Statements.
No other new accounting pronouncement issued or effective during the fiscal year had or is expected to have a material impact on the Consolidated Financial Statements.
Off-Balance sheet Arrangements
We do not maintain off-balance sheet arrangements nor do we participate in any non-exchange traded contracts requiring fair value accounting treatment other than the operating leases as disclosed in Item 2, Properties and Notes to Consolidated Financial Statements (Note 10).
36
Item 7A. Quantitative and Qualitative Disclosures About Market Risk
This item is not applicable to smaller reporting companies.
Item 8. Financial Statements and Supplementary Data
Set for below beginning with page F-1.
Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
None
Item 9A. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
As of August 31, 2016, under the supervision and with the participation of our Chief Executive Officer (Principal Executive Officer), and Chief Financial Officer (Principal Financial Officer), management has evaluated the effectiveness of the design and operations of the Company’s disclosure controls and procedures. Based on that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that the Company’s disclosure controls and procedures were not effective as of August 31, 2016 as a result of the material weakness in internal control over financial reporting discussed below.
Management’s Report on Internal Control Over Financial Reporting
Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in the Securities Exchange Act of 1934 Rule 13a-15(f). Our Chief Executive Officer and Chief Financial Officer conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework in Internal Control — Integrated Framework, issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO Framework”).
37
The Company’s management assessed the effectiveness of the Company’s internal control over financial reporting as of August 31, 2016. Based on this evaluation, management concluded that our internal control over financial reporting was not effective as of August 31, 2016. Our Chief Executive Officer and Chief Financial Officer concluded we have a material weakness due to lack of segregation of duties and a limited corporate governance structure.
Our size has prevented us from being able to employ sufficient resources to enable us to have an adequate level of supervision and segregation of duties within our internal control system. Therefore while there are some compensating controls in place, it is difficult to ensure effective segregation of accounting and financial reporting duties. Management reported a material weakness resulting from the combination of the following significant deficiencies:· Lack of segregation of duties in certain accounting and financial reporting processes including the approval and execution of disbursements;· The Company’s corporate governance responsibilities are performed by the Board of Directors; we do not have independent Board of Directors, we do not have an audit committee or compensation committee. Because our Board of Directors only meets periodically throughout the year, several of our corporate governance functions are not performed concurrent (or timely) with the underlying transaction, evaluation, or recordation of the transaction.
While we strive to segregate duties as much as practicable, there is an insufficient volume of transactions at this point in time to justify additional full time staff. We believe that this is typical in most exploration stage companies. We may not be able to fully remediate the material weakness until we commence significant sales of our PetLife products at which time we would expect to hire more staff. We will continue to monitor and assess the costs and benefits of additional staffing.
In light of the above material weakness, we performed additional analyses and procedures in order to conclude that our consolidated financial statements for the years ended August 31, 2015 and August 31, 2016 included in this Annual Report on Form 10-K were fairly stated in accordance with US GAAP. Accordingly, management believes that despite our material weaknesses, our consolidated financial statements for the years ended August 31, 2015 and August 31, 2016 are fairly stated, in all material respects, in accordance with US GAAP.
This report does not include an attestation report of the Company’s independent registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by the Company’s independent registered public accounting firm pursuant to temporary rules of the SEC that permit the Company to provide only management’s report on internal control in this annual report.
There were no significant changes in internal control over financial reporting that occurred during the last fiscal quarter covered by this report that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.
38
Item 10. Directors, Executive Officers and Corporate Governance Identify Directors and Executive Officers
Executive Officers and Directors
The following table sets forth information regarding the Company’s executive officers and directors. There is no agreement or understanding between the Company and each current or proposed director or executive officer pursuant to which he was selected as an officer or director.
| Name | Age | Position | ||
| Ralph T. Salvagno, MD | 60 | Chairman and Chief Executive Officer | ||
| Joel Beth Mitchell Navratik, DVM | 49 | Vice President – Veterinary Affairs | ||
| Dr. Vivek Ramana | 57 | Chief Medical Officer |
Ralph T. Salvagno, MD. Dr. Salvagno is Chairman of the Board and CEO of Petlife Pharmaceuticals Inc. and a practicing Orthopaedic Surgeon. From his early childhood he has always had family pets. From purebred Golden Retrievers to stray mixed breeds, dogs were always a part of his life. More recently, his affinity has been for felines. His children are now all adults but he has 3 cats that he cares for with his wife Tracy.
A Bachelor of Science Honors graduate of the University of Maryland, Dr. Salvagno received his M.D. degree from the University of Maryland Medical School and completed an Orthopaedic Surgery residency at Case Western Reserve University/ University Hospitals of Cleveland. Since 1987 he has been in private practice and is the founding partner and president of the Center for Joint Surgery and Sports Medicine in Hagerstown, Md.
Dr. Salvagno specializes in adult reconstructive surgery including joint replacement of the hip, knee and shoulder. His practice also include general orthopaedic trauma and he has a special interest in biotechnology and regenerative medicine. He is Board Certified in Orthopaedic Surgery and a fellow of the American Academy of Orthopaedic Surgeons.
His professional memberships include the American Medical Association, the American Academy of Hip and Knee Surgeons, the American Association for Physician Leadership and the International Society for Stem Cell Research. He has presented new technology for arthritis treatment at recent national meetings.
Dr. Salvagno has previously served on the Board of the Washington County Arthritis Foundation and served for 10 years on the Board of Meritus Enterprises, the for-profit arm of Meritus Medical Center. Dr. Salvagno currently serves as Vice Chief of Staff at Meritus Medical Center in Hagerstown, Md. He is Medical Director of Saving Lives Initiative – Sierra Leone and recently completed the first surgical mission to Sierra Leone since the Ebola crisis.
39
Joel Beth Mitchell Navratik, DVM. Dr. Mitchell Navratik holds a Bachelor of Science Degree in Zoology and a Doctorate in Veterinary Medicine from the University of Florida. After university, she undertook an internship in Small Animal Medicine and Surgery at The Animal Medical Center and Bobst Hospital in New York City in 1994. That same years, she joined the Aventura Animal Hospital and was soon promoted to the position of Chief of Staff within the facility. This is a position she has held since then. One of her biggest achievements at the facility has been to expand Aventura Animal Hospital to a full service hospital with an emergency care unit that is open 24 hours a day, 7 days a week. Since 2001, Dr. Joel Beth Mitchell Navratik has served as the Corporate Medical Director for Pet Medical Centers, LLC. in South Florida. Pet Medical Centers is comprised of 8 state of the art small animal veterinary hospitals employing 27 veterinarians and 162 staff members. Pet Medical Centers offers a comprehensive approach to Veterinary Care, which includes internal medicine, surgery, radiology, ultrasound, CT imaging, boarding, grooming, preventive medicine and a fully stocked pharmacy. Pet Medical Centers is the largest privately held group of veterinary hospitals in the Unites States. Dr. Mitchell Navratik holds a bachelor of Science from the University of Florida and a Doctor of Veterinary Medicine from the University of Florida.
Dr. Vivek Ramana. Prior to joining PetLife, Dr. Ramana served as Senior Safety Medical Officer/Senior Medical Director for Ambit Biosciences. In 2008 - 2009, Dr. Ramana served as Senior Medical Director/Therapeutic Area Lead for US Astellas. From 2006 to 2008 he was Chief Medical Officer and President for AdPharma. From 2003 to 2006, he served as Vice President, Medical Services at Ovation Pharmaceuticals. During the early part of Dr. Ramana’s career, from 1984 to 2003, Dr. Ramana served as Medical Director of R&D for Pharmaceutical Clinical Research, Inc., which involved joint ventures with BMS, Pfizer, Schering Plough, and Astra Zeneca.
Dr. Ramana received his medical degree from the University of Belgrade, Serbia and specialized in Radiation Oncology and Clinical Pathology. Post Graduate studies in Molecular Immunology, Genetics and Molecular Biology from University of New Haven, CT; Post-Doctoral Studies in Clinical Pharmacology, Drug Research & Development and Regulation from TUFTS University in Boston.
Family Relationships
There are no family relationships among the Company’s existing or incoming directors or officers.
Board and Director Independence
The Company utilizes the definition of “independent” set forth in the listing standards of The NASDAQ Stock Market, LLC (“Nasdaq”). Currently, the Company believes that none of its directors would be considered independent. As discussed below, the Company currently does not have a standing audit committee, compensation committee or nominating committee or any other standing committees.
Corporate Governance
The entire board of directors serves as the audit committee. The board presently does not have an “audit committee financial expert,” as such term is defined under the securities laws. The board does not believe it is necessary to have a financial expert, given the early stage of the Company’s commercial operations and limited financial resources and activities. The Company believes that none of its directors would be considered “independent,” applying the Nasdaq listing standards for independence for members of an audit committee.
The Company is not required to have and does not have a compensation committee. The Company does not believe it is necessary for the board of directors to appoint a compensation committee because the volume of compensation matters that will come before the board for consideration permits the entire board to give sufficient time and attention to such matters to be involved in all decision making. The Company has not paid any compensation to its executive officers or directors in the last two fiscal years. The entire board participates in consideration of executive officer and director compensation. The Company expects that the board will make all decisions regarding executive officer compensation. The board will consider the recommendations of the Chief Executive Officer when determining compensation for the other executive officers. The Chief Executive Officer will have no role in determining his own compensation. The Company has not paid any fee to or otherwise engaged any compensation consultants.
40
The Company also is not required to have and does not have a nominating committee. Given the limited scope of the Company’s operations, the board believes appointing a nominating committee would be premature and of little assistance until the Company’s business operations are at a more advanced level.
The Company does not have a written policy or formal procedural requirements for stockholders to submit recommendations for director nominations. However, the board will consider recommendations from stockholders. Stockholders should communicate nominee suggestions directly to the board and accompany the recommendation with biographical details and a statement of support for the nominee. The suggested nominee must also provide a statement of consent to being considered for nomination.
The entire board of directors decides on nominees. The board reviews any written information provided with respect to the candidates and interviews the candidates. Although there are no formal criteria for nominees, the board believes that persons should be actively engaged in business endeavors, have a financial background, be familiar with acquisition strategies and money management and be able to promote a diversity of views based on the person’s education, experience and professional employment. Based on the information gathered, the board then makes a decision on whether to recommend the candidates as nominees for director. The committee does not distinguish among nominees recommended by stockholders and other persons. The Company does not pay any fee to or otherwise engage any third party or parties to identify or evaluate or assist in identifying or evaluating potential nominees. Though the committee does not have specific guidelines on diversity, it is one of many criteria considered by the board when evaluating candidates.
Corporate Governance
The entire board of directors serves as the audit committee. The board presently does not have an “audit committee financial expert,” as such term is defined under the securities laws. The board does not believe it is necessary to have a financial expert, given the early stage of the Company’s commercial operations and limited financial resources and activities. The Company believes that none of its directors would be considered “independent,” applying the Nasdaq listing standards for independence for members of an audit committee.
The Company is not required to have and does not have a compensation committee. The Company does not believe it is necessary for the board of directors to appoint a compensation committee because the volume of compensation matters that will come before the board for consideration permits the entire board to give sufficient time and attention to such matters to be involved in all decision making. The Company has not paid any compensation to its executive officers or directors in the last two fiscal years. The entire board participates in consideration of executive officer and director compensation. The Company expects that the board will make all decisions regarding executive officer compensation. The board will consider the recommendations of the Chief Executive Officer when determining compensation for the other executive officers. The Chief Executive Officer will have no role in determining his own compensation. The Company has not paid any fee to or otherwise engaged any compensation consultants.
41
The Company also is not required to have and does not have a nominating committee. Given the limited scope of the Company’s operations, the board believes appointing a nominating committee would be premature and of little assistance until the Company’s business operations are at a more advanced level.
The Company does not have a written policy or formal procedural requirements for stockholders to submit recommendations for director nominations. However, the board will consider recommendations from stockholders. Stockholders should communicate nominee suggestions directly to the board and accompany the recommendation with biographical details and a statement of support for the nominee. The suggested nominee must also provide a statement of consent to being considered for nomination.
The entire board of directors decides on nominees. The board reviews any written information provided with respect to the candidates and interviews the candidates. Although there are no formal criteria for nominees, the board believes that persons should be actively engaged in business endeavors, have a financial background, be familiar with acquisition strategies and money management and be able to promote a diversity of views based on the person’s education, experience and professional employment. Based on the information gathered, the board then makes a decision on whether to recommend the candidates as nominees for director. The committee does not distinguish among nominees recommended by stockholders and other persons. The Company does not pay any fee to or otherwise engage any third party or parties to identify or evaluate or assist in identifying or evaluating potential nominees. Though the committee does not have specific guidelines on diversity, it is one of many criteria considered by the board when evaluating candidates.
Significant Employees
We have no significant employees other than our chief executive officer and chief financial officer.
Board Meetings
During the fiscal year ended August 31, 2016, we had one director. During the year fiscal year ended August 31, 2016, the Board held one meeting and has taken numerous actions by unanimous written consent.
Shareholder Communications
We do not have a formal shareholder communications process. Shareholders are welcome to communicate with the Company by forwarding correspondence to Petlife Pharmaceuticals, Inc., 38 West Main Street, Hancock, MD 21750, Attn.: Shareholder Relations.
42
Section 16(a) Beneficial Ownership Reporting Compliance
Section 16(a) of the Exchange Act, requires the Company’s officers and directors, and persons who own more than 10% of the Company’s Common Stock, to file reports of ownership and changes in ownership of the Company’s Common Stock with the SEC. To our knowledge, during the fiscal year ended August 31, 2016, based solely on a review of such materials as are required by the SEC, all required reporting is current and accurate.
Code of Business Conduct and Ethics
We have adopted a code of business conduct and ethics that applies to all of our executive officers and employees. The Code addresses conflicts of interest, compliance with all laws and other legal requirements, conduct of business in an honest and ethical manner, integrity and actions in the Company’s best interest. Directors, officers and employees are required to report any conduct that they believe in good faith to be an actual or apparent violation of the Code. The Sarbanes-Oxley Act of 2002 requires companies to have procedures to receive, retain and treat complaints received regarding accounting, internal accounting controls or auditing matters and to allow for the confidential and anonymous submission by employees of concerns regarding questionable accounting or auditing matters. The Company currently has such procedures in place.
43
Item 11. Executive Compensation
Summary Compensation Table
The following table summarizes all compensation recorded by us in the period for the years ended August 31, 2016 and 2015 for our named executive officers.
| Name and Principal Position | Year | Salary | Bonus | Stock Awards | Option Awards | Non-Equity Incentive Plan Compensation | Nonquali-fied Deferred Compensation Earnings | All other Compensation | Total | ||||||||||||||||||||||||||
| Ralph Salvagno, | 2015 | - | - | - | - | - | - | - | - | ||||||||||||||||||||||||||
| CEO | 2016 | - | - | $ | 840,000 | $ | 204,849 | - | - | - | $ | 1,044,849 | |||||||||||||||||||||||
| Dr. Joel Mitchell | 2015 | - | - | - | - | - | - | - | - | ||||||||||||||||||||||||||
| 2016 | - | - | $ | 50,000 | - | - | - | - | $ | 50,000 | |||||||||||||||||||||||||
Executive Employment Agreements
We currently have employment agreements with Dr. Joel Mitchell, Dr. Ralph Salvagno and Dr Ramana. See notes to the financial statements.
Equity Compensation Plans
We have no current equity compensation plans.
Outstanding Equity Awards at Fiscal Year-end
There are 2,000,000 and 0 stock option equity awards outstanding for our Executive officers for the years ended August 31, 2016 and August 31, 2015, respectively.
Stock Option Exercised
There were no stock options exercised on common shares during the years ended August 31, 2016 and August 31, 2015.
Expense Reimbursement
We will reimburse our officers and directors for reasonable expenses incurred during the course of their performance.
44
Retirement Plans and Benefits.
None.
Standard Director Compensation Arrangement
We do not have a standard compensation arrangement for directors.
Indemnification and Limitation on Liability of Directors
Our Articles of Incorporation and Bylaws provide that we must indemnify, to the fullest extent permitted by the laws of the State of Nevada, any of our directors, officers, employees or agents made or threatened to be made a party to a proceeding, by reason of the person serving or having served in a capacity as such, against judgments, penalties, fines, settlements and reasonable expenses incurred by the person in connection with the proceeding if certain standards are met.
The Nevada Revised Statutes allows indemnification of directors, officers, employees and agents of a company against liabilities incurred in any proceeding in which an individual is made a party because he or she was a director, officer, employee or agent of the company if such person conducted himself in good faith and reasonably believed his actions were in, or not opposed to, the best interests of the company, and with respect to any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful. A person must be found to be entitled to indemnification under this statutory standard by procedures designed to assure that disinterested members of the board of directors have approved indemnification or that, absent the ability to obtain sufficient numbers of disinterested directors, independent counsel or shareholders have approved the indemnification based on a finding that the person has met the standard. Indemnification is limited to reasonable expenses.
At present, there is no pending litigation or proceeding involving any of our directors, officers, employees or agents where indemnification will be required or permitted. Insofar as indemnification for liabilities arising under the 1933 Act may be permitted to our directors, officers and controlling persons pursuant to the foregoing provisions, or otherwise, we have been advised that in the opinion of the SEC, such indemnification is against public policy as expressed in the 1933 Act and is, therefore, unenforceable.
Our Articles of Incorporation limit the liability of our directors to the fullest extent permitted by law. Specifically, our directors will not be personally liable for monetary damages for breach of fiduciary duty as directors, except for:
● any breach of the duty of loyalty to us or our stockholders;
● acts or omissions not in good faith or that involved intentional misconduct or a knowing violation of law;
● dividends or other distributions of corporate assets that are in contravention of certain statutory or contractual restrictions;
● violations of certain laws; or
● any transaction from which the director derives an improper personal benefit.
45
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
The following table sets forth the number of shares of common stock beneficially owned by (i) those persons or groups known to beneficially own more than 5% of the Company's common stock, (ii) each current director and executive officer of the Company, and (iii) all the current executive officers and directors as a group. The information is set forth as of our fiscal year end August 31, 2016.
Pursuant to Rule 13d-3 under the Exchange Act, a beneficial owner of securities is a person who directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise has, or shares, voting power and/or investment power with respect to the securities, and any person who has the right to acquire beneficial ownership of the security within 60 days through any means, including the exercise of any option, warrant or right or the conversion of a security. Any shares that are not outstanding that a person has the right to acquire are deemed to be outstanding for the purpose of calculating the percentage of beneficial ownership of such person, but are not deemed to be outstanding for the purpose of calculating the percentage of beneficial ownership of any other person. The shares of capital stock listed reflect the exchange of 1 share for every 20 shares of common stock effective August 12, 2014, and also reflect the 1 for 5 reverse exchange of its shares completed in September 2016, which resulted in a total of 8,399,422 shares issued and outstanding at August 31, 2016. As of December 6, 2016 there are 59,686,681 shares outstanding.
| Title of Class | Name and Address of Beneficial Owner | Amount and Nature of Beneficial Ownership | Percentage of Common Stock | |||||||
| Common Stock | Irrevocable de Fidecomison Confianza General De Familiar Irrevocable (1) | 2,362,400 | 28.1 | % | ||||||
| Common Stock | Elite International Partners, Inc. (2) | 1,098,388 | 13.1 | % | ||||||
| Common Stock | Grand Street Ventures (3) | 1,140,000 | 13.6 | % | ||||||
| Common Stock | Ralph T. Salvagno, MD (3) | 1,140,000 | 13.6 | % | ||||||
| Common Stock | Dr. Vivek Ramana (1) | 30,000 | 1.7 | % | ||||||
| Common Stock | Joel Beth Mitchell Navratik | 0 | .004 | % | ||||||
| Common Stock | All officers and directors (3 persons) | 1,170,000 | 13.9 | % | ||||||
| (1) | The trust was formed for the benefit of Arthur Mikaelian, our previous Chief Executive Officer. | |
| (2) | Elite International Partners, Inc. is beneficial owned by Richard Langley. | |
| (3) | Grand Street Ventures is beneficially owned by our Chief Executive Officer and Chairman of the Board, Ralph T. Salvagno, MD. |
46
The scorpion reservation that we use is owned by Medolife. We will enter into a definitive agreement with Medolife for our utilization of that reservation in the manufacture and preparation of our products.
Most of our current employees, including without limitation all employees who are engaged in research and development, are also employed or otherwise work for Medolife Corporation.
Item 13. Certain Relationships and Related Transactions, and Director Independence
The scorpion reservation that we use is owned by Medolife. We will enter into a definitive agreement with Medolife for our utilization of that reservation in the manufacture and preparation of our products.
Most of our current employees, including without limitation all employees who are engaged in research and development, are also employed or otherwise work for Medolife Corporation.
Item 14. Principal Accountant Fees and Services
The Company engaged LBB & Associates Ltd., LLP (“LBB”) as its independent registered public accounting firm for the Company’s fiscal year ended August 31, 2016, and 2015. LBB remains the Company’s accounting firm.
The following table sets forth fees billed to us by LBB during the fiscal years ended August 31, 2016 and 2015 for: (i) services rendered for the audit of our annual consolidated financial statements and the review of our quarterly consolidated financial statements, (ii) services by our auditor that are reasonably related to the performance of the audit or review of our consolidated financial statements and that are not reported as Audit Fees, (iii) services rendered in connection with tax compliance, tax advice and tax planning, and (iv) all other fees for services rendered.
| Fiscal Years Ended | ||||||||
| August 31, 2016 | August 31, 2015 | |||||||
| Audit Fees (1) | $ | 18,400 | $ | 24,000 | ||||
| Audit Related Fees (2) | - | - | ||||||
| Tax Fess (3) | - | - | ||||||
| All Other Fees (4) | - | - | ||||||
| $ | 18,400 | $ | 24,000 | |||||
(1) Audit Fees
Audit fees include fees incurred for professional services rendered in connection with the audit of the Company’s annual consolidated financial statements for the two years ended August 31, 2016 and for the reviews of the quarterly interim consolidated financial statements included in the Company’s Forms 10-Q for the fiscal years ended August 31, 2014 and August 31, 2016.
47
(2) Audit-Related Fees
(3) Tax Fees
No fees of this sort were billed for the years ended August 31, 2016 and 2015.
(4) All Other Fees
No fees of this sort were billed for the years ended August 31, 2016 and 2015.
Policy on Pre-Approval of Audit and Permissible Non-audit Services of Independent Auditors
Consistent with the SEC policies regarding auditor independence, our Board of Directors has responsibility for appointing, setting compensation and overseeing the work of the independent auditor. In recognition of this responsibility, our Board of Directors has established a policy to pre-approve all audit and permissible non-audit services provided by the independent auditor.
Prior to engagement of the independent auditor for the next year’s audit, management will submit an aggregate of services expected to be rendered during that year for each of the following four categories of services to the Board of Directors for approval.
Item 15. Exhibits and Financial Statement Schedules
See the Exhibit Index and the Index to Financial Statements immediately following the signature page of this report.
48
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Annual Report on Form 10-K for the fiscal year ended August 31, 2016 to be signed on its behalf by the undersigned, thereunto duly authorized.
| Petlife Pharmaceuticals, Inc. | ||
| December 21, 2016 | ||
| By: | /s/ Ralph Salvagno | |
| Ralph Salvagno | ||
| Chief Executive Officer, Director | ||
| /s/ Ralph Salvagno | ||
| Ralph Salvagno | ||
| Chief Financial & Principal Accounting Officer | ||
49
Exhibits
| Exhibit No. | Description | |
| 2.1 | Agreement and Plan of Merger dated as of June 26, 2014 between Eco Ventures Group, Inc. and PetLife Pharmaceuticals, Inc. (i) | |
| 3.2 | Bylaws (ii) | |
| 10.1 | Reorganization Agreement dated as of April 28, 2014 by and between Eco Ventures Group, Inc. and PetLife Corporation (i) | |
| 10.2 | Patent License Agreement dated as of August 1, 2014 between Arthur Grant Mikaelian and Petlife Pharmaceuticals, Inc. (i) | |
| 10.3 | Manufacturing Agreement dated as of May 8, 2014 between Petlife Corporation and Samson Pharmaceuticals, Inc. (i) | |
| 31.1 | Certification Pursuant to Rule 13A-14 or 15D-14 of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 signed by the Principal Executive Officer | |
| 31.2 | Certification Pursuant to Rule 13A-14 or 15D-14 of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 signed by the Principal Financial Officer | |
| 32.1 | Certification Required by 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 signed by Principal Executive Officer and Chief Financial Officer | |
| 101 | Interactive data files |
(i) Incorporated herein by reference to the Company’s Periodic Report on Form 8-K filed on April 8, 2014.
(ii) Incorporated herein by reference to the Company’s Annual Report on Form 10-K filed on December 16, 2014.
50
PETLIFE PHARMACEUTICALS, INC.
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
51
LBB & ASSOCIATES LTD., LLP
10260 Westheimer Road, Suite 310
Houston, TX 77042
Phone: (713) 800-4343 Fax: (713) 456-2408
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Stockholders and Board of Directors of
Petlife Pharmaceuticals, Inc.
Hancock, MD
We have audited the accompanying consolidated balance sheets of Petlife Pharmaceuticals, Inc. (the “Company”) as of August 31, 2016 and 2015, and the related consolidated statements of operations, stockholders’ deficit, and cash flows for the years then. These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits.
We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audits include consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting.
Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the consolidated financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall consolidated financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.
In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the consolidated financial position of Petlife Pharmaceuticals, Inc., as of August 31, 2016 and 2015, and the results of its consolidated operations, stockholders’ deficit, and its cash flows for the years ended August 31, 2016 and 2015, in conformity with accounting principles generally accepted in the United States of America.
As discussed in Note 2 to the consolidated financial statements, the Company’s absence of significant revenues, recurring losses from operations, and its need for additional financing in order to fund its projected loss in 2017 raise substantial doubt about its ability to continue as a going concern. The 2016 consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.
/S/ LBB & ASSOCIATES LTD., LLP
LBB & Associates Ltd., LLP
Houston, Texas
December 21, 2016
52
| PETLIFE PHARMACEUTICALS, INC. |
| Consolidated Balance Sheets |
| 2016 | 2015 | |||||||
| ASSETS | ||||||||
| Current assets | ||||||||
| Cash | $ | 1,172 | $ | - | ||||
| Due from affiliate | - | 4,800 | ||||||
| Total current assets | 1,172 | 4,800 | ||||||
| Website development | - | 600 | ||||||
| Total assets | $ | 1,172 | $ | 5,400 | ||||
| LIABILITIES AND STOCKHOLDERS' DEFICIT | ||||||||
| Current liabilities | ||||||||
| Accounts payable and accrued expense | $ | 291,547 | $ | 235,427 | ||||
| Accounts payable and accrued expense - related party | 466,474 | 125,100 | ||||||
| Stock payable | 2,315,000 | - | ||||||
| Loan from officer | 153,011 | - | ||||||
| Due - shareholder | 10,000 | 10,000 | ||||||
| Total current liabilities | 3,236,032 | 370,527 | ||||||
| Total liabilities | 3,236,032 | 370,527 | ||||||
| Commitments | ||||||||
| STOCKHOLDERS' DEFICIT | ||||||||
| Preferred stock, $0.001 par value, 50,000,000 authorized, 0 and 0 shares issued and outstanding, respectively | - | - | ||||||
| Common stock, $0.001 par value, 750,000,000 authorized, 8,399,422 and 11,706,431 shares issued and outstanding, respectively | 8,400 | 11,707 | ||||||
| Additional paid-in capital | 3,888,070 | 3,067,456 | ||||||
| Accumulated deficit | (7,131,330 | ) | (3,444,290 | ) | ||||
| Total stockholders' deficit | (3,234,860 | ) | (365,127 | ) | ||||
| Total liabilities and stockholders' deficit | $ | 1,172 | $ | 5,400 | ||||
The accompanying notes are an integral part of these financial statements.
53
| PETLIFE PHARMACEUTICALS, INC. |
| Consolidated Statement of Operations |
| Year ended | Year ended | |||||||
| August 31, 2016 | August 31, 2015 | |||||||
| Revenue | $ | - | $ | - | ||||
| Operating Expenses | ||||||||
| Manufacturing and production | - | 220,733 | ||||||
| General and administrative | 3,687,040 | 1,711,468 | ||||||
| 3,687,040 | 1,932,201 | |||||||
| Operating loss | (3,687,040 | ) | (1,932,201 | ) | ||||
| Net loss | $ | (3,687,040 | ) | $ | (1,932,201 | ) | ||
| Net loss per share - basic and diluted | $ | (0.40 | ) | $ | (0.17 | ) | ||
| Weighted average shares outstanding - basic and diluted | 9,124,246 | 11,459,583 | ||||||
The accompanying notes are an integral part of these financial statements.
54
| PETLIFE PHARMACEUTICALS, INC. |
| Consolidated Statements of Stockholders' Deficit |
| Year ended August 31, 2016 and 2015 |
| Common Stock | Additional Paid-in | Accumulated | ||||||||||||||||||
| Shares | Amount | Capital | Deficit | Total | ||||||||||||||||
| Balance August 31, 2014 | 10,926,811 | 10,927 | 1,518,596 | (1,512,089 | ) | 17,434 | ||||||||||||||
| Stock-based compensation | 779,620 | 780 | 1,548,860 | - | 1,549,640 | |||||||||||||||
| Net loss | - | - | - | (1,932,201 | ) | (1,932,201 | ) | |||||||||||||
| Balance August 31, 2015 | 11,706,431 | 11,707 | 3,067,456 | (3,444,290 | ) | (365,127 | ) | |||||||||||||
| Shares cancelled by principals | (3,538,249 | ) | (3,538 | ) | 3,538 | - | - | |||||||||||||
| Common shares for accounts payable | 231,240 | 231 | 80,702 | - | 80,933 | |||||||||||||||
| Stock-based compensation | - | - | 736,374 | - | 736,374 | |||||||||||||||
| Net loss | - | - | - | (3,687,040 | ) | (3,687,040 | ) | |||||||||||||
| Balance August 31, 2016 | 8,399,422 | 8,400 | 3,888,070 | (7,131,330 | ) | (3,234,860 | ) | |||||||||||||
The accompanying notes are an integral part of these financial statements.
55
| PETLIFE PHARMACEUTICALS, INC. |
| Consolidated Statements of Cash Flow |
| Year ended | Year ended | |||||||
| August 31, 2016 | August 31, 2015 | |||||||
| Net Cash used in operating activities | ||||||||
| Net loss | $ | (3,687,040 | ) | $ | (1,932,201 | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Impairment of website development | 600 | - | ||||||
| Bad debt | 4,800 | - | ||||||
| Stock-based compensation | 736,374 | 1,549,640 | ||||||
| Changes in assets and liabilities: | ||||||||
| Accounts payable and accrued expenses | 56,120 | 235,427 | ||||||
| Accounts payable and accrued expenses - related party | 422,307 | 125,100 | ||||||
| Stock payable | 2,315,000 | - | ||||||
| Net cash used in operating activities | (151,839 | ) | (22,034 | ) | ||||
| Net cash used in investing activities | ||||||||
| Capital expenditures | - | (600 | ) | |||||
| Net cash used in investing activities | - | (600 | ) | |||||
| Net cash provided by financing activities | ||||||||
| Due from affiliate, net | - | 5,782 | ||||||
| Proceeds from loan from officer | 153,011 | - | ||||||
| Proceeds from shareholder advance | - | 10,000 | ||||||
| Net cash provided by financing activities | 153,011 | 15,782 | ||||||
| Increase (decrease) in cash | 1,172 | (6,852 | ) | |||||
| Commitments | - | - | ||||||
| Cash, beginning of period | - | 6,852 | ||||||
| Cash, end of period | $ | 1,172 | $ | - | ||||
| Supplemental disclosure of cash flow information: | ||||||||
| Income taxes paid | $ | - | $ | - | ||||
| Interest expense paid | $ | - | $ | - | ||||
| Non-cash transaction | ||||||||
| Common shares for accounts payable | $ | 80,933 | $ | - | ||||
| Common shares returned to treasury and cancelled | $ | 3,538 | $ | - | ||||
The accompanying notes are an integral part of these financial statements.
56
PETLIFE PHARMACEUTICALS, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
AUGUST 31, 2016 and 2015
NOTE 1 – SIGNIFICANT ACCOUNTING POLICIES
Nature of Operations
PetLife Pharmaceuticals, Inc. (“Company”) is a registered U.S. Veterinary Pharmaceutical company whose mission is to bring its scientifically proven, potentiated bioactive medication and nutraceuticals — “Vitalzul” — to the world of veterinary oncology. The Company specializes in the research, development, sales and support of advanced drugs and nutraceuticals for pet cancer and autoimmune related diseases such as arthritis.
A summary of the significant accounting policies applied in the presentation of the accompanying consolidated financial statements follows:
Basis and business presentation
The Company was incorporated on April 5, 2002 under the laws of the State of Nevada as “Aztek Ventures Inc.” Effective November 13, 2007, we filed a Certificate of Amendment to our Articles of Incorporation to change our name from “Aztek Ventures Inc.” to “Genesis Uranium Corp.” Effective April 21, 2008, we amended our Articles of Incorporation to change our name from “Genesis Uranium Corp.” to “Vault Technology Inc.” to reflect the change in our business focus beyond solely that of uranium exploration. Effective July 10, 2009, we filed a Certificate of Amendment to our Articles of Incorporation to change our name from “Vault Technology, Inc.” to “Modern Renewable Technologies, Inc.” (“Modern”). On May 27, 2011, Modern, merged with Eco Ventures Group, Inc., and the name of the Company was changed to Eco Ventures Group, Inc. On July 15, 2013, the Company entered into an Agreement and Plan of Merger with Clear TV Ventures, Inc. Under the terms of the merger, Clear TV became the surviving corporation. On June 26, 2014, Eco Ventures Group, Inc. entered into an Agreement and Plan of Merger with its subsidiary, PetLife Pharmaceuticals, Inc., a Nevada Corporation, with PetLife Pharmaceuticals, Inc. being the surviving entity. As part of that merger, the name of the Company was changed to PetLife Pharmaceuticals, Inc. and each 15 shares of our common stock were exchanged for one share in the surviving company. Effective August 12, 2014 we completed the closing of the Share Exchange Agreement and the acquisition of Petlife and changed our name to Petlife Pharmaceuticals, Inc. On July 20, 2016, Petlife Pharmaceuticals, Inc. entered into an Agreement and Plan of Merger with its wholly-owned subsidiary, PetLife Merger Subsidiary, Inc., a Nevada Corporation, with PetLife Merger Subsidiary, Inc. being the surviving entity. As part of that merger, the name of the Petlife Merger Subsidiary was changed back to PetLife Pharmaceuticals, Inc. The purpose of the subsidiary merger was to effectuate a 1 for 5 reverse exchange of Petlife’s common stock pursuant to the terms of the merger. The combined entities continue on public markets pursuant to Rule 12g-3 of the Securities Exchange Act of 1934, as amended.
All references herein to the number of shares outstanding and per-share amounts have been retroactively restated to reflect the exchange ratios referenced above.
All references that refer to (the “Company” or “PetLife Pharmaceuticals, Inc.” or “Petlife” or “we” or “us” or “our”) are PetLife Pharmaceuticals, Inc., the Registrant and its wholly and or majority owned subsidiaries. We are in the development stage, as defined by Accounting Standards Codification subtopic 915-10, Development Stage Entities (“ASC 915-10”) and have developed and is launching a new generation of potentiated veterinary cancer medications and nutraceuticals, based on the same patented formula “Escozine” and production processes that have been scientifically proven as an effective treatment for cancer in humans for years. We have not generated any revenues to date, have incurred expenses and has sustained losses since December 12, 2012 (date of inception). Consequently, our operations are subject to all the risks inherent in the establishment of a new business enterprise. We have accumulated a deficit of approximately $4,700,000.
The consolidated financial statements include the accounts of the Company and its majority owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.
57
PETLIFE PHARMACEUTICALS, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
AUGUST 31, 2016 and 2015
Merger and Corporate Restructure
On July 20, 2016, Petlife Pharmaceuticals, Inc. entered into an Agreement and Plan of Merger with its wholly-owned subsidiary, PetLife Merger Subsidiary, Inc., a Nevada Corporation, with PetLife Merger Subsidiary, Inc. being the surviving entity. As part of that merger, the name of the Petlife Merger Subsidiary was changed back to PetLife Pharmaceuticals, Inc. The purpose of the subsidiary merger was to effectuate a 1 for 5 reverse exchange of Petlife’s common stock pursuant to the terms of the merger. The combined entities continue on public markets pursuant to Rule 12g-3 of the Securities Exchange Act of 1934, as amended.
Accordingly, the historical financial statements are those of Petlife, the accounting acquirer, immediately following the consummation of the reverse acquisition. The Company did not recognize goodwill or any intangible assets in connection with this transaction.
Estimates
The preparation of the financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates.
Cash
The Company considers cash to consist of cash on hand and temporary investments having an original maturity of 90 days or less that are readily convertible into cash.
Property and Equipment
Property and equipment are stated at cost. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings.
Income Taxes
The Company has adopted Accounting Standards Codification subtopic 740-10, Income Taxes (“ASC 740-10”) which requires the recognition of deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the financial statement or tax returns. Under this method, deferred tax liabilities and assets are determined based on the difference between financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Temporary differences between taxable income reported for financial reporting purposes and income tax purposes consist primarily of timing differences such as deferred officers’ compensation and stock based compensation accounting.
58
PETLIFE PHARMACEUTICALS, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
AUGUST 31, 2016 and 2015
Net Loss per Common Share, basic and diluted
The Company has adopted Accounting Standards Codification subtopic 260-10, Earnings Per Share (“ASC 260-10”) specifying the computation, presentation and disclosure requirements of earnings per share information. Basic loss per share has been calculated based upon the weighted average number of common shares outstanding.
Stock based compensation
The Company follows Accounting Standards Codification subtopic 718-10, Compensation (“ASC 718-10”) which requires that all share-based payments to both employees and non-employees be recognized in the income statement based on their fair values.
Concentrations of Credit Risk
Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash, cash equivalents and trade receivables. The Company places its cash and temporary cash investments with high credit quality institutions. At times, such investments may be in excess of the FDIC insurance limit.
Research and Development
The Company accounts for research and development costs in accordance with Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved as defined under the applicable agreement. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company incurred costs of $0 and $0 for research and development expenses for the years ended August 31, 2016 and 2015.
Fair Value
Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”) requires disclosure of the fair value of certain financial instruments. The carrying amount reported in the unaudited condensed consolidated balance sheet for accounts payable and accrued expenses, advances and notes payable approximates fair value because of the immediate or short-term maturity of these financial instruments.
59
PETLIFE PHARMACEUTICALS, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
AUGUST 31, 2016 and 2015
Recent Accounting Pronouncements
No other new accounting pronouncement issued or effective during the fiscal year had or is expected to have a material impact on the Consolidated Financial Statements.
NOTE 2 – GOING CONCERN
The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As shown in the accompanying consolidated financial statements as of August 31, 2016, the Company has an accumulated deficit of approximately $7,000,000. As of August 31, 2016, the Company’s absence of revenues, recurring losses and its need for additional financing to operate and fund its projected loss in 2017 raise substantial doubt about its ability to continue as a going concern.
The Company’s existence is currently dependent upon management’s ability to develop profitable operations and or upon obtaining additional financing to carry out its planned business. Management is devoting substantially all of its efforts to the commercialization of its planned products, as well as raising additional debt or equity financing in order to accelerate the development and commercialization of additional products. There can be no assurance that the Company’s commercialization or financing efforts will result in profitable operations or the resolution of the Company’s liquidity problems.
There can be no assurance that any additional financings will be available to the Company on satisfactory terms and conditions, if at all. In the event the Company is unable to continue as a going concern, it may elect or require to seek protection from its creditors by filing a voluntary petition in bankruptcy or may be subject to an involuntary petition in bankruptcy. To date, management has not considered this alternative, nor does management view it as a likely occurrence.
The accompanying consolidated statements do not include any adjustments relating to the recoverability of assets and classification of assets and liabilities that might be necessary should the Company be unable to continue as a going concern.
NOTE 3 – STOCKHOLDERS’ DEFICIT
Common Stock
Per the merger referred to above (Note 1), the Company effectuated a 1 for 5 reverse exchange on July 20, 2016. This has been retroactively accounted for in the financial statements.
During the year ended August 31, 2015, the Company issued 779,620 shares of its $.001 par value common stock for services valued at $1,549,640.
Effective November 20, 2015, principals of the Company cancelled and returned to treasury a total of 3,538,249 shares of common stock.
Also, effective November 20, 2015, the Company issued a total of 231,240 shares of common stock to investors, officers, and employees of the Company for $80,933 of accounts payable.
60
PETLIFE PHARMACEUTICALS, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
AUGUST 31, 2016 and 2015
On June 9, 2016, the Company entered into an agreement with Dr. Ralph Salvagno our chief executive officer. The agreement is for 24 months or until June 30, 2018 with options to renew for additional 24 months. The Company is to pay an annual salary of $240,000, issue 8,000,000 of common stock that vest immediately. The Company granted 2,000,000 options to purchase 2,000,000 shares of common stock at 50% discount to market or $0.25, whichever is higher. For the year ended August 31, 2016, the Company recorded stock based compensation of $840,000 for the common stock which is not yet issued as of August 31, 2016 and recorded in payables.
Upon receipt of FDA approval for Escozine for Pets, Dr. Salvagno will receive an additional 5,000,000 shares of common stock and will be granted options to purchase an additional 2,000,000 shares of common stock at 50% discount to market or $1.00, whichever is higher, this event has not occurred as of August 31, 2016.
The Black-Scholes pricing model was used to estimate the fair value of the 2,000,000 options issued during the year, using the assumptions of a risk free interest rate of .77%, dividend yield of 0%, volatility of 340%, and an expected life of 2 years. These options were expensed immediately in the amount of approximately $205,000.
On June 13, 2016, the Company entered into an agreement with a consultant for financial services. The agreement is for 36 months or until June 2019 with options to renew for additional 24 months. The Company is to issue 5,000,000 shares of common stock that vest immediately. The Company granted 2,000,000 options to purchase 2,000,000 shares of common stock at 50% discount to market or $0.25, whichever is higher. For the year ended August 31, 2016, the Company recorded stock based compensation of $1,350,000 for the common stock which is not yet issued as of August 31, 2016 and recorded in payables.
The Black-Scholes pricing model was used to estimate the fair value of the 2,000,000 options issued during the year, using the assumptions of a risk free interest rate of .73%, dividend yield of 0%, volatility of 339%, and an expected life of 2 years. These options were expensed immediately in the amount of approximately $531,000.
In June 2016, the Company entered into an agreement with our science officer. The agreement is for 36 months or until June 2019 with options to renew for additional 24 months. The Company is to pay an annual salary of $48,000 in year 1, $72,000 in year 2, and $96,000 in year 3 and to also issue up to 1,000,000 shares of common stock valued at $300,000 that vest over 2 years. For the year ended August 31, 2016, the Company recorded stock based compensation of $25,000 and there remains $275,000 to be expensed; these shares have not been issued as of August 31, 2016 and recorded in payables.
In June 2016, the Company entered into an agreement with an employee for 36 months or until June 2019 with options to renew for additional 24 months. The Company is to pay salary of $10,000 per month and to issue up to 3,000,000 shares of common stock valued at $900,000 that vest over 3 years. For the year ended August 31, 2016, the Company recorded stock based compensation of $50,000 and there remains $850,000 to be expensed; these shares have not been issued as of August 31, 2016 and recorded in payables.
In June 2016, the Company entered into an agreement with an employee for 36 months or until June 2019 with options to renew for additional 24 months. The Company is to pay annual salary of $30,000 year, $54,000 year 2, and $78,000 year 3 and to issue up to 2,000,000 shares of common stock valued at $600,000 that vest over 2 years. For the year ended August 31, 2016, the Company recorded stock based compensation of $50,000 and there remains $550,000 to be expensed ; these shares have not been issued as of August 31, 2016 and recorded in payables.
61
PETLIFE PHARMACEUTICALS, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
AUGUST 31, 2016 and 2015
Options
The Company granted 4,000,000 options to purchase 4,000,000 shares of common stock at 50% discount to market or $0.25, whichever is higher. The options have a 2 year term and vest immediately.
Option activity for the years ended August 31, 2016 and 2015, was as follows:
| Shares | Weighted average exercise price | Weighted average remaining life (yrs) | Grant
date fair value | |||||||||||||
| Outstanding – August 31, 2014 | - | $ | - | - | $ | - | ||||||||||
| Options granted | - | - | - | - | ||||||||||||
| Options exercised | - | - | - | - | ||||||||||||
| Options forfeited | - | - | - | - | ||||||||||||
| Outstanding – August 31, 2015 | - | - | - | - | ||||||||||||
| Options granted | 4,000,000 | .25 | 2.00 | 736,374 | ||||||||||||
| Options exercised | - | - | - | - | ||||||||||||
| Options forfeited | - | - | - | - | ||||||||||||
| Outstanding – August 31, 2016 | 4,000,000 | $ | .25 | 1.77 | $ | 736,374 | ||||||||||
| Vested at August 31, 2016 | 4,000,000 | $ | .25 | 1.77 | $ | 736,374 | ||||||||||
| Exercisable at August 31, 2016 | 4,000,000 | $ | .25 | 1.77 | $ | 736,374 | ||||||||||
NOTE 4 - RELATED PARTY TRANSACTIONS
On December 30, 2013, the Company entered into an agreement with Medolife Corporation (“Medolife), an affiliated company, for the performance of certain ongoing services and maintenance related to a scorpion reservation , together with the providing of other services such as product operations, research and development to support the Company’s product marketing. During the year ended August 31, 2014 Medolife invoiced the Company for services and maintenance of $165,800. During year ended August 31, 2014, Medolife received proceeds from the sale of the Company’s common stock totaling $184,500. The Company was owed $4,800 from Medolife as of August 31, 2015. As of August 31, 2016 the Company has written off the receivable to bad debt.
On August 1, 2014, the Company entered into a patent license agreement with a shareholder for a polarized scorpion venom solution and a method for making polarized scorpion venom solution for veterinary use. The licensor has provided Medolife, an affiliated company by common shareholders, with an exclusive right to the polarized scorpion venom patent with the exception of the rights for veterinary use. The Company will manufacture, use, and sell polarized scorpion venom containing such patented improvements for veterinary use.
During the year ended August 31, 2015, we received $10,000 from a shareholder advance which is unsecured, non-interest bearing, and due on demand.
During the year ended August 31, 2016, we received a $153,011 loan from an officer which accrues 2% interest (4% if in default), unsecured, and due on demand.
As August 31, 2016 and 2015 there is related party accounts payable and accrued expense of $466,474 and $125,100, respectively.
62
PETLIFE PHARMACEUTICALS, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
AUGUST 31, 2016 and 2015
NOTE 5 - INCOME TAXES
The Company follows ASC 740-10-50 “Accounting for Income Taxes.” Deferred income taxes reflect the net effect of (a) temporary difference between carrying amounts of assets and liabilities for financial purposes and the amounts used for income tax reporting purposes, and (b) net operating loss carry-forwards. No net provision for refundable Federal income tax has been made in the accompanying statement of loss because no recoverable taxes were paid previously. Similarly, no deferred tax asset attributable to the net operating loss carry-forward has been recognized, as it is not deemed likely to be realized.
The provision for refundable federal income tax consists of the following for the years ending:
| August 31, 2016 | August 31, 2015 | |||||||
| Federal income tax benefit attributed to: | ||||||||
| Net operating loss | $ | 1,254,000 | $ | 657,000 | ||||
| Valuation allowance | (1,254,000 | ) | (657,000 | ) | ||||
| Net benefit | $ | - | $ | - | ||||
The cumulative tax effect at the expected rate of 34% of significant items comprising our net deferred tax amount is as follows:
| August 31, 2016 | August 31, 2015 | |||||||
| Deferred tax attributed: | ||||||||
| Net operating loss carryover | $ | 2,425,000 | $ | 1,171,000 | ||||
| Less: change in valuation allowance | (2,425,000 | ) | (1,171,000 | ) | ||||
| Net deferred tax asset | $ | - | $ | - | ||||
At August 31, 2016, the Company had an unused net operating loss carry-forward approximating $7,000,000 that is available to offset future taxable income; the loss carry-forward will start to expire in 2033.
NOTE 6 COMMITMENTS
On February 1, 2016 the Company entered into a lease space effective June 1, 2016 through May 30, 2018. Lease payments of $750 per month payable in advance on the first day of each month for total lease payments of $18,000.
NOTE 7 SUBSEQUENT EVENTS
In October of 2016 the Company issued 51,286,689 shares of common stock to certain insiders, employees, and other accredited investors for services and other consideration.
In October 2016, the Company entered into an agreement with an employee for a monthly salary of $6,300. The agreement is for 12 months or until October 2017 with options to renew for additional 12 months. The Company is to issue 20,000 shares of common stock on the 15th of each month for the term of the agreement.
In October 2016, the Company entered into an agreement for consulting services for $400 per hour. The agreement is for 12 months or until October 2017 with options to renew for additional 12 months. The Company is to issue up to 250,000 shares of common stock upon FDA approval of Vitalzul/CBD combination.
In November 2016, the Company entered into an agreement with an employee for a monthly salary of $2,500. The agreement is for 12 months or until November 2017 with options to renew for additional 12 months. The Company is to issue 10,000 shares of common stock after 90 days of continuous employment and 10,000 shares per month for 9 months thereafter.
In October, 2016, the Company issued a promissory note for $150,000 bearing interest at 10% per annum and is due November 1, 2017. The promissory note is payable from 25% of all proceeds raised after November 1, 2016. In connection with the promissory note, the Company issued 250,000 shares of common stock.
On September 1, 2016 the Company entered into a consulting agreement for investor relations with a term of 6 months and fees of $10,000 cash payment due on signing of contract and on 1st day of each month, $25,000 ancillary budget due each month for the balance of this contract, 500,000 shares of common stock to be issued upon the day of execution of the agreement with a vesting schedule of 1/3 per month for the extent of the contract, and the Company will reimburse Consultant for any pre-approved travel or other expenses.
Subsequent to year end August 31, 2016 the Company received loans from an officer of $77,732 which accrues 2% interest (4% if in default), unsecured, and due on demand.
63